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ABSTRACT 
Human immunodeficiency virus 1 (HIV-1) is a lentivirus belonging to the 
retroviridae family that leads to the development of acquired immunodeficiency 
syndrome (AIDS) via the destruction of CD4+ T cells. The cellular host protein TRIM5α 
found in rhesus macaques (rhTRIM5α) can prevent HIV-1 infection via an early bock to 
infection after entry of the virion into target cells. The mechanism of restriction is poorly 
understood; however, treatment of rhTRIM5α expressing cells with inhibitors to a 
cellular degradation pathway, the proteasome, relieves an intermediate step of the viral 
life cycle, although infection remains restricted by TRIM5α. Interestingly, treatment of 
rhTRIM5α expressing cells with proteasomal inhibitors does not alter rhTRIM5α protein 
turnover. The role of a second cellular degradation pathway, the autophagy-lysosomal 
pathway, in TRIM5α mediated restriction has not been explored. Lysosomal degradation 
occurs within double membrane vesicles, derived from the endoplasmic reticulum. 
Delivery of proteins to lysosomes can occur via diverse mechanisms, such as 
macroautophagy, microautophagy or chaperone mediated autophagy (CMA). Previously, 
TRIM5α was shown to interact with two proteins, p62 and Hsc70, necessary for 
autophagic degradation via selective macroautophagy and chaperone mediated 
autophagy, respectively. 
In the present study, we provide evidence that rhTRIM5α is degraded via 
chaperone mediated autophagy. Using inhibitors of lysosomal degradation, we show that 
rhTRIM5α protein turnover decreases and rhTRIM5α subcellular localization is altered. 
Additionally, we show that human TRIM5α protein degradation is inhibited when 
ix 
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lysosomal degradation is inhibited. These data indicate that lysosomal degradation is 
responsible for TRIM5α protein turnover. We found that treatment with lysosomal 
inhibitors increased the co-localization between TRIM5α and proteins important for 
autophagy-lysosomal degradation. We show that when macroautophagy is inhibited, 
TRIM5α protein degradation remains sensitive to lysosomal inhibition. We found that 
genetic inhibition of CMA prevented rhTRIM5α turnover, indicating that CMA may be 
the pathway responsible for rhTRIM5α degradation. Furthermore, we identify a CMA 
targeting motif within the coiled-coil domain of rhTRIM5α that decreases rhTRIM5α 
sensitivity to lysosomal inhibitors, indicating that rhTRIM5α is degraded by CMA .  
Our data suggests that rhTRIM5α degraded by the lysosome, specifically 
chaperone mediated autophagy. Therefore, we hypothesized that the lysosomal 
degradation of TRIM5α is important for viral restriction. When rhTRIM5α expressing 
cells were treated with lysosomal inhibitors, there was no difference in the level of viral 
intermediates, while proteasomal inhibitors could restore these intermediates to similar 
levels as the unrestricted control cells. We also used siRNA specific for a lysosomal 
protein important for CMA. Under these conditions, we observed a slight, but statistically 
significant, decrease in viral intermediates. Additionally, we observed increased 
restriction of B tropic murine leukemia virus (B-MLV) infectivity, which is usually 
unaffected by TRIM5α. Therefore, we conclude that TRIM5α is degraded by chaperone 
mediated autophagy and that inhibition of chaperone mediated autophagy can enhance 
TRIM5α mediated restriction.
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CHAPTER ONE 
INTRODUCTION 
Human immunodeficiency virus  
 Human immunodeficiency virus 1 (HIV-1) is a lentivirus belonging to the 
retroviridae family. HIV-1 is the infectious agent that leads to acquired 
immunodeficiency syndrome (AIDS), which emerged in human populations in the early 
1980s. Since its discovery, HIV-1 and AIDS have been identified as a major epidemic in 
the 20
th
 and 21
st
 centuries. As of 2011, it was estimated that 34.2 million people were 
living with HIV, with 2.5 million people newly infected that year. In 2011 alone, 1.7 
million people died from AIDS (Piot and Quinn 2013). 
 Patients infected with HIV-1 initially suffer from non-specific symptoms such as 
fever, sore throat and rash (Schacker, Collier et al. 1996). Patients with AIDS often 
succumb to fatal opportunistic infections and malignancies, which is due to a deficiency 
in CD4+ T cells (Gottlieb, Schroff et al. 1981; Masur, Michelis et al. 1981). Specifically, 
activated CD4+ CCR5+ T cells were soon identified as the major cell type infected by 
HIV-1 (Swanstrom and Coffin 2012).  
Initial infection with HIV-1 leads to the development of non-specific symptoms. 
Interestingly, HIV-1 can lead to a depletion of CD4+ T cells within the gut associated 
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lymphoid tissue (GALT) with no concurrent development of gastrointestinal distress 
(Swanstrom and Coffin 2012). Viremia, as measured by viral RNA copies in the blood 
plasma, can range from <40 copies/ml to 100,000 copies/ml. AIDS develops when the 
CD4+ T cell count falls below 200 cells/l blood plasmid (Lackner, Lederman et al. 
2012). With early antiviral treatment, immune function improves, leading to a decreased 
risk of complications. It is estimated that people with HIV-1 who receive early treatment 
can approach survival rates similar to the uninfected population. In fact, with advent of 
highly active anti-retroviral therapy (HARRT), the causes of death in AIDS patients has 
shifted from opportunistic infections to cardiovascular disease, renal insuffiency and a 
variety of malignant disorders (Lackner, Lederman et al. 2012).  
Patients infected with HIV-1 have a diminished T cell response as the initial 
target of infection is activated CD4+ T cells. CD4 is the primary receptor for HIV-1. 
Early in infection, the virus uses the cytokine CCR5 as a co-receptor. As the virus 
evolves and spreads, there is an emergence of viruses with altered cellular tropism. This 
causes the virus to spread to different cell types such as macrophages. Additionally, the 
virus glycoproteins can evolve to use a new co-receptor, CXCR4 (Wilen, Tilton et al. 
2012). The emergence of so-called X4 and macrophage tropic viruses indicates a poor 
patient prognosis, as more cells can be infected and destroyed by the virus (Hunt, 
Harrigan et al. 2006; Swanstrom and Coffin 2012).  
The HIV-1 genome consists of two copies of positive strand RNA packaged 
within the viral nucleocapsid complex (Lu, Heng et al. 2011). This is encapsidated by 
1500 capsid protein (CA) monomers (Arhel 2010). The virus is packaged in an envelope 
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derived from the host cell plasma membrane (Figure 1). Upon infection of a target cell, 
the virus glycoprotein, gp120, engages the plasma membrane receptor CD4 (Freed 1998). 
Through the interaction of a co-receptor, fusion between the viral envelope and host cell 
plasma membrane occurs to allow for the release of viral core (consisting of viral CA and 
nucleoprotein complexed together) into the host cell cytoplasm. The virus undergoes a 
process of CA disassembly known as uncoating, either concurrent or immediately 
preceding viral reverse transcription. The reverse transcribed viral genome, which exists 
as a double stranded DNA product, translocates into the nucleus. The virus genome 
integrates into the host genome, a reaction that is catalyzed by the viral integrase protein 
(Figure 1).  The initial steps of viral infection and replication have been extensively 
studied in an attempt to identify and develop antiviral targets.    
 
Tripartite motif containing proteins 
The tripartite motif (TRIM) family of proteins is a large, structurally diverse 
group of host proteins that are implicated in the prevention of viral infection (Perron, 
Stremlau et al. 2004; Stremlau, Owens et al. 2004; Uchil, Hinz et al. 2013; Versteeg, 
Rajsbaum et al. 2013). The TRIM is characterized N-terminally to C-terminally by a 
Really Interesting Gene (RING) domain, one or two Bbox domains, and a coiled–coil 
domain (CC) (Reddy, Etkin et al. 1992). The first large scale identification of TRIM 
family members was performed by Reymond et al. Using a bioinformatics approach, 37 
TRIM family members, and 34 new TRIM splice variants in mammals were identified 
(Reymond, Meroni et al. 2001). This study demonstrated that TRIM proteins could 
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Figure 1 Steps in the retroviral life cycle. Schematic highlighting the process of viral 
entry and exit. The viral glycoprotein engages the primary receptor CD4 (co-receptors are 
not indicated). This leads to fusion of the viral membrane with the host cell plasma 
membrane to allow for the viral core to enter the cytoplasm. Partial uncoating of the viral 
nuclocapsid and reverse transcription occur in the cytoplasm. The reverse transcribed 
genome enters the nucleus and is incorporated into the host chromosome, a process 
catalyzed by the viral integrase. Viral transcription occurs via the cellular RNA 
polymerase II (RNAPII) and the viral RNA products are exported out of the nucleus. 
These products can serve as the new viral genome and be packaged into the viral particle 
or they can serve as the mRNA templates to produce viral proteins. The viral particle is 
assembled and released at the plasmid membrane. 
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assemble into unique cellular accumulations when exogenously expressed in HeLa or 
U2OS cells. Since this initial characterization, close to 100 mammalian TRIM proteins 
have been described (Han, D. et al. 2011). Many of these TRIM genes are controlled 
through interferon (IFN), both type I and II, indicating a conserved role for TRIM 
proteins in the host antiviral response (Carthagena, Bergamaschi et al. 2009). 
Additionally, many large scale, systematic screens of TRIM protein have shown this 
family to be involved in restriction of retroviruses, RNA viruses, and DNA viruses 
(Uchil, Quinlan et al. 2008; Uchil, Hinz et al. 2013; Versteeg, Rajsbaum et al. 2013). 
The various domains of the TRIM confer unique functions on the protein, namely 
E3 ubiquitin ligase function from the RING domain, higher order multimerization from 
the B-box domain(s) and dimerization from the CC domain (Meroni and Diez-Roux 
2005); (Reymond, Meroni et al. 2001). Diversity within the TRIM family comes from the 
C-terminal domain, with the majority of TRIM proteins containing a B30.2/SPRY 
domain, which allows for protein-protein interactions (Napolitano and Meroni 2012) 
(Figure 2). The RING domain of TRIM proteins has been implicated in protein 
ubiquitination on Lysine 48 (K48) or Lysine 63 (K63), which can lead to diverse 
outcomes within the cell such as proteasomal degradation, NFB signaling, DNA repair 
and protein targeting to the lysosome (Deshaies and Joazeiro 2009; Ye and Rape 2009). 
Additionally, TRIM proteins can interact with E2 proteins important for SUMOylation 
and ISGylation (Zou and Zhang 2006; Chu and Yang 2011; Napolitano and Meroni 
2012). Therefore, TRIM proteins may represent a cache of proteins involved in numerous 
cellular processes.   
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Figure 2. TRIM proteins are characterized by the C-terminal domain. There are over 
100 human TRIM genes. TRIM proteins are identified by the conserved N-terminal 
RING-BBox-coiled coil (RBCC) domain. TRIM proteins are divided into 13 subfamilies 
based on the C-terminal domains. 
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TRIM5: Species specific retroviral restriction factor 
The first TRIM protein that was found to prevent viral infection was a variant of 
TRIM5, TRIM5α. Specifically, Stremlau et al. found that TRIM5α from rhesus macaques 
(rhTRIM5α) can potently prevent HIV-1 infection (Stremlau, Owens et al. 2004). Even 
before the identification of rhTRIM5α, it was known that rhesus macaques could not be 
productively infected by HIV-1; that this block in infection occurred after viral entry into 
target cells; and that this inhibition was dependent on the viral capsid (CA) (Bieniasz 
2003). Indeed, Stremlau et al. demonstrated that rhTRIM5α acted early to prevent the 
formation of late reverse transcript (RT) products, which are necessary for productive 
infection (Stremlau, Owens et al. 2004). Interestingly, the human ortholog of TRIM5α 
(huTRIM5α) demonstrated a less potent block to HIV-1 infection, although it could 
potently inhibit N tropic murine leukemia virus (N-MLV) and equine infectious anemia 
virus (EIAV) (Keckesova, Ylinen et al. 2004; Perron, Stremlau et al. 2004; Stremlau, 
Owens et al. 2004; Yap, Nisole et al. 2004). B tropic MLV (B-MLV) is unaffected by 
either rhTRIM5α or huTRIM5α, unless residue 110 is changed to the amino acid in the 
N-MLV capsid. When this single amino acid change was made, B-MLV was now 
susceptible to huTRIM5α restriction (Perron, Stremlau et al. 2004). This led to the 
hypothesis that TRIM5α acts a species specific barrier to retroviral infection. Indeed, as 
more TRIM5α orthologs were identified from different primates, the evidence for this 
hypothesis grew as some primate TRIM5α genes could restrict simian immunodefiency 
virus (SIV) isolated from a different primate species. For example, SIV isolated from 
macaques (SIVmac) was not restricted by rhTRIM5α. However, squirrel monkey  
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rhTRIM5α could restrict SIVmac (Nakayama and Shioda 2012). In all cases, the specific 
retroviral CA was targeted by the TRIM5α C-terminal domain, which in most TRIM5α 
orthologs contains a SPRY domain. The exception is found in Owl Monkeys and some 
macaques (Malim and Bieniasz 2012). Genetic events have led to the fusion of TRIM5 to 
cyclophilin A (CypA), in which CypA replaces the SPRY domain of the TRIM5 gene, 
generating a fusion protein known as TRIMCyp. The replacement of the SPRY domain 
with CypA still allows for TRIMCyp to recognize and bind the retroviral capsid, as CypA 
naturally binds the capsid. The TRIMCyp fusion proteins bind the CA of HIV-1 to 
various degrees among different species (Virgen, Kratovac et al. 2008; Price, Marzetta et 
al. 2009).  
The SPRY domain of TRIM5α contains amino acid determinants that provide 
specificity for the retroviral capsid. Specifically, there are three variable regions within 
the SPRY domain of TRIM5α that have signatures of positive selection, indicating that 
residues within these regions can adapt to recognize different capsid of lentiviruses 
(Sawyer, Wu et al. 2005; Song, Gold et al. 2005; Stremlau, Perron et al. 2005; Ohkura, 
Yap et al. 2006). There are additional residues within the CC domain of TRIM5α that 
demonstrate similar positive selection (Johnson and Sawyer 2009). Collectively, these 
results indicate that rhTRIM5α acts as a retroviral restriction factor that recognizes 
specific retroviral capsids via evolutionarily selected residues within the C-terminal 
SPRY domain.  
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Possible mechanisms of retroviral restriction by rhTRIM5α 
The mechanism of retroviral restriction by TRIM5α is not fully understood. While 
it was postulated that the E3 ubiquitin ligase activity found in the RING domain of 
TRIM5α could lead to the ubiquitination and proteasomal dependent degradation of the 
HIV-1 CA, no evidence to date has demonstrated this. Therefore, several models of 
TRIM5α mediated restriction have been proposed.  
One of the earliest models proposed was described by Stremlau et al. In this 
model,  TRIM5α can facilitate the rapid, premature degradation of the retroviral capsid 
(Stremlau, Perron et al. 2006). In these studies, TRIM5α led to the loss of CA protein that 
had not disassociated from the intact viral core, while not changing the total amount of 
CA protein. This led to the conclusion that TRIM5α can cause capsid disassembly while 
not degrading the CA protein itself (Stremlau, Perron et al. 2006). Similar results were 
observed for huTRIM5α and TRIMCyp (Diaz-Griffero, Kar et al. 2007).  
A second model of TRIM5α restriction involves a two-step mechanism of 
restriction first proposed by Anderson et al. In this model, TRIM5α can bind the 
retroviral CA via the SPRY domain, which is sufficient to inhibit retroviral infection. The 
second step of this model proposed the disassembly of the virion via TRIM5α mediated 
proteasomal degradation (Sastri and Campbell 2011). Evidence for this model first came 
from studies performed by Wu et al. and Anderson et al. These studies identified a role 
for the proteasome in rhTRIM5α restriction by demonstrating the production of viral late 
RT products and competent pre-integration complexes (PICs) when rhTRIM5α restrictive 
cells are treated with the proteasomal inhibitor, MG132 (Wu, Anderson et al. 2006); 
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(Anderson, Campbell et al. 2006). In spite of this apparent relief of restriction when 
MG132 was present, 2 LTR circles, a measure of viral import into the nucleus, and 
infection (as measured by viral DNA integration into the host chromosome) remained 
restricted (Wu, Anderson et al. 2006). Similarly, the ability of TRIMCyp to restrict HIV-
1 infectivity remained restricted with proteasomal inhibition (Perez-Caballero, 
Hatziioannou et al. 2005). Additionally, Campbell et al. described the sequestration of 
HIV-1 virions within rhTRIM5α cytoplasmic assemblies upon treatment with 
proteasomal inhibitors, although this sequestration was not necessary for viral restriction. 
Therefore, retroviral restriction mediated by rhTRIM5α involves a proteasomal-
independent intermediate consisting of HIV-1 CA surrounded by rhTRIM5α (Campbell, 
Perez et al. 2008). However, the use of proteasomal inhibitors did not lead to the 
accumulation of rhTRIM5α protein, indicating that the ubiquitin-proteasome system is 
not the degradative pathway responsible for rhTRIM5α protein turnover.  
A third model of TRIM5α restriction also describes the loss of CA in in TRIM5α 
expressing cells. This model proposes that the removal of the CA protein from the 
nucleoprotein complexes prevents proper infection from occurring (Chatterji, Bobardt et 
al. 2006). Specifically, HIV-1 infected cells expressing TRIM5α were fractionated into 
cytosolic and vesicular fractions, and specific CA protein degradation was measured. CA 
protein was degraded independent of the degradation of other nucleoprotein components. 
Furthermore, the authors demonstrated that CA degradation was proteasome independent, 
as degradation was unaffected with proteasomal inhibitors.  
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Cellular degradation pathways  
Cellular protein turnover is mediated by two pathways in eukaryotic cells: the 
ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway. Together, 
these pathways control the degradation of proteins, leading to the recycling of the amino 
acid pool for new protein synthesis and the replenishing of energy stores. Additionally, 
both pathways have been implicated in a variety of human diseases such as Parkinson’s 
disease, viral and bacterial infections and control of the immune response.  
 
Ubiquitin-proteasome system 
The 26S proteasome is a multiprotein barrel complex that degrades individual, 
ubiquitinated proteins (Saeki and Tanaka 2012). Substrate proteins are often short-lived, 
indicating that the 26S proteasome is involved in attenuation of cellular signaling 
(Schreiber and Peter 2013). Proteins are degraded into small peptides which can be 
digested into single amino acids by the large protease, tripeptidyl peptidase (Chuang, 
Rockel et al. 2010). The 26S proteasome is comprised of the 20S proteolytic core and the 
19S regulatory particle (Murata, Yashiroda et al. 2009). Degradation of proteins by the 
26S proteasome requires ATP binding to subunits within the regulatory particle (Smith, 
Chang et al. 2007; Gillette, Kumar et al. 2008; Lander, Estrin et al. 2012). The 20S core 
contains the proteolytic residues within a central channel, and access is regulated by the 
19S regulatory particle (Groll, Ditzel et al. 1997; Smith, Chang et al. 2007; Gillette, 
Kumar et al. 2008; Lander, Estrin et al. 2012). The 19S particle can either be at both ends 
of the channel or only at a single end (da Fonseca and Morris 2008). The 19S particle 
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also serves as the substrate recognition site and promotes deubiquitination, unfolding and 
translocation of the substrate proteins into the 20S core (Smith, Chang et al. 2007; 
Gillette, Kumar et al. 2008; Lander, Estrin et al. 2012). Within the base of the 19S 
particle lies the subunits that bind ATP to open the entry gate for substrate translocation 
(Tian, Park et al. 2011).  
Proteins are targeted to the proteasome via a 76-amino acid protein called 
ubiquitin (Weissman 2001). The process of ubiquitination involves the covalent linkage 
of ubiquitin to a substrate protein via step-wise enzymatic reaction between the C-
terminal glycine of ubiquitin to a lysine within the substrate protein (Kerscher, 
Felberbaum et al. 2006). When the site of conjugation occurs at a lysine within in the 
substrate protein, this is called monoubiquitinaiton. Additionally, ubiquitin molecules can 
be linked together through one of the seven lysine molecules throughout the protein, 
yielding branched ubiquitin chains. Additionally, linear polyubiquitin chains are formed 
via the N-terminal -amino group in ubiquitin (Schreiber and Peter 2013). The ubiquitin 
modification can occur in multiple sites throughout the ubiquitin molecule, with K48 and 
K63 linked ubiquitin chains being the most prevalent. It was thought that K48-linked 
polyubiquitin chains are responsible for targeting proteins to the proteasome for 
degradation (Chau, Tobias et al. 1989; Thrower, Hoffman et al. 2000). However, more 
and more evidence shows that all types of ubiquitin modifications (polyubiquitin chains 
at different lysines, monoubiquitination and multi-monoubiquitination) can lead to 
protein targeting to the proteasome (Kirkpatrick, Hathaway et al. 2006; Jin, Williamson 
et al. 2008). Ubiquitination is a multi-enzyme, stepwise process. The first step involves 
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the E1 ubiquitin-activating enzyme. Using ATP, a single ubiquitin molecule is activated 
at the C-terminal glycine to form a thiol-ester linkage with the cysteine residue of the E1 
ubiquitin activating domain. This ubiquitin is then transferred to an E2 ubiquitin 
conjugating enzyme via another thiol-ester linkage. In the final step, the ubiquitin is 
conjugated to a lysine residue within the target protein with the help of the E3 ubiquitin 
ligase enzyme (Yeh, Gong et al. 2000). The target protein could be an entirely different 
protein or the E3 ubiquitin ligase itself (Yamauchi, Wada et al. 2008). There are 
estimated to be hundreds of E3 ubiquitin ligases, and their congnate deubiquitinases 
(Nijman, Luna-Vargas et al. 2005). Substrate specificity is dictated by the E3 ubiquitin 
ligase (Nagy and Dikic 2010). In this way, the role for E3 ubiquitin ligases in 
proteasomal degradation has been heavily investigated.    
 
Autophagic-lysosomal degradation 
Autophagy is derived from the Greek words “auto” (self) and “phagy” (eating) 
and encompasses three separate pathways that all lead to degradation of proteins by 
lysosomes (Yorimitsu and Klionsky 2005). Degradation in the lysosome is mediated by 
proteases, lipases, nucleotidases and glycases, implicating the lysosome as the major 
organelle responsible for macromolcular recycling (Kroemer and Jaattela 2005; Park and 
Cuervo 2013). Autophagy is thought to be the main pathway activated to degrade target 
proteins during cellular stress; however numerous studies have shown that proteins 
targeted to the autophagy-lysosomal pathway under normal cellular conditions as well 
(Komatsu, Waguri et al. 2005; Hara, Nakamura et al. 2006; Komatsu, Waguri et al. 2006; 
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Massey, Kaushik et al. 2006; Nakai, Yamaguchi et al. 2007; Liu, Wang et al. 2009). 
Three separate pathways encompass the autophagy-lysosomal pathway, delineated by the 
respective route of cargo delivery. These pathways are macroautophagy, microautophagy 
and chaperone mediated autophagy (CMA).  
 
Macroautophagy 
Macroautophagy is the bulk degradation of cytosolic proteins enclosed within a 
membrane that leads to the formation of the autophagsome. Macroautophagy can 
selectively and non-selectively degrade target proteins. There are more than 30 autophagy 
related genes (Atgs) responsible for macroautophagy (Klionsky, Codogno et al. 2010). 
Autophagosome formation occurs within the phagophore assembly site (PAS) (Schreiber 
and Peter 2013). Initiation of macroautophagy involves the inactivation of mTOR, the 
mammalian target of rapamycin, in response to specific stimuli such as reduced growth 
factors or cellular stress. Upon downregulation of mTOR, Ulk1/2 is dephosphorylated 
and its kinase activity is initiated. Dephosphorylation of Ulk1/2 leads to increased 
assembly of Ulk1/2-Agt13 complexes which are crucial for the initiation of 
macroautophagy (Weidberg, Shvets et al. 2011). Membrane lipids derived from the 
plasma membrane, the ER, the mitochondria and the Golgi apparatus are recruited to the 
PAS (Razi, Chan et al. 2009; Hailey, Rambold et al. 2010; Ravikumar, Moreau et al. 
2010; Suzuki and Ohsumi 2010). Activated Ulk1/2 associates with the initiating 
phagophore membrane (Weidberg, Shvets et al. 2011). A second kinase complex is 
recruited to the site of autophagosomal formation. This complex is comprised of Beclin-
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1, Vps34 and Vps15 as the core proteins (Furuya, Yu et al. 2005; Yan, Flinn et al. 2009). 
This complex phosphorylates the lipid molecules derived from the above cellular 
structures, specifically phosphoinositides (PIs), generating phosphatidylionsitol-3-
phosphate (PI3P). PI3P recruits other effectors to the phagophore membrane, which in 
turn recruit other Atg proteins to the phagophore membrane (Reggiori, Komatsu et al. 
2012).  
Elongation of the phagophore membrane depends on the recruitment of two 
conjugation systems, the Atg5-Atg12-Atg16 complex and LC3 conjugation to 
phosphatidyle ethanolamine (LC3-II). These two conjugation systems resemble the 
conjugation of ubiquitin to target proteins via the stepwise conjugation of Atg proteins. 
The Atg5/12/16 system depends on the covalent and irreversible linkage of Atg12 to 
Atg5, mediated by Atg7 (E1-like enzyme) and Atg10 (E2-like enzyme). Then, Atg16 
interacts with Atg5, leading to the formation of a complex crucial for the early stages of 
autophagy. The conjugation of LC3 to PE is mediated by 1) cleavage by Atg4; 2) 
conjugation of cleaved LC3 to Atg7; 3) transfer to Atg3 (E2-like); and 4) covalent bond 
formed between LC3 and PE. This complex serves as a marker of the autophagosome 
until the degradation within the lysosome (Weidberg, Shvets et al. 2011). Both the 
Atg5/12/16 and LC3-PE conjugation systems are important for the isolation membrane 
elongation and autophagosomal closure. Additionally, LC3 has been implicated in cargo 
recruitment. The autophagosome then matures and fuses with late endosomes and 
lysosomes, which is mediated by SNARE and lipid-modifying proteins (Vergne and 
Deretic 2010; Dall'Armi, Devereaux et al. 2013; Park and Cuervo 2013). In addition to 
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bulk sequestration of cytoplasmic contents by the phagophore, there is increasing 
evidence of selective macroautophagy for certain cargos, such as mitochondria, 
pathogens, lipid droplets and other proteins. Selective macroautophagy is facilitated by 
the recognition of specific cargo by molecules such as p62, NBR1, or NDP52 and the 
binding of specific autophagy proteins, such as LC3. For example, the cellular scaffold 
proteins can recognize and bind ubiquitinated target proteins via the UBA domain. Then, 
through the interaction with LC3 via the LC3 interacting region (LIR), p62 can deliver 
ubiquitinated proteins to the autophagosome.  
 
Microautophagy 
Microautophagy is the engulfment of cytosolic contents via invagination on the 
lysosomal membrane and was first described by de Duve and Wattiaux (De Duve and 
Wattiaux 1966). Most of the research covering microautophagy has used yeast as the 
model organism (Mijaljica, Prescott et al. 2011). Similar to macroautophagy, 
microautophagy in yeast can be selective and non-selective (Kunz, Schwarz et al. 2004). 
Nonselective microautophagy is the random sequestration of cytosolic components. 
Selective microautophagy leads to the degradation of specific organelles (Farre, Krick et 
al. 2009). In higher eukaryotes, research suggests that microautophagy is present and 
active in addition to the well-established lysosomal degradation pathways such as 
macroautophagy and CMA. For example, Marzella et al. demonstrated that lysosomes 
can show microautophagy activity in vitro (Marzella, Ahlberg et al. 1980). Additionally, 
a lysosomal wrapping mechanism with features similar to microautophagy has been 
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described (Sakai and Ogawa 1982; Sakai, Araki et al. 1989). Finally, Moritmore et al. 
demonstrated a correlation between changes in the cellular environment and 
microautophagy  in mouse hepatocytes during starvation (Mortimore, Hutson et al. 1983). 
More recently, Sahu et al. found that microautophagic mechanisms can facilitate 
cytosolic protein delivery to late endosomes. This led to the identification of a 
microautophagy-like, selective process distinct from CMA mediated by the cellular 
chaperone Hsc70 (Sahu, Kaushik et al. 2011).  
 
Chaperone mediated autophagy 
The term chaperone mediate autophagy (CMA) is somewhat of a misnomer as the 
pathway does not involve the de novo formation of the autophagosome. Instead, CMA 
occurs completely within the lysosome alone. CMA is a selective form of protein 
degradation mediated by the recognition of a pentapeptide motif by cellular chaperones. 
Backer et al. identified this sequence using the cleaved forms of RNase A, RNase S-
peptide (residues 1-20) and RNase S-protein (residues 21-124). This cleavage event 
dramatically changed the half-life of the two fragments. Similar to full length RNase A, 
RNase S-peptide was degraded faster when cells were serum starved (Backer, Bourret et 
al. 1983). Furthermore, when the 20 amino acids of RNase S-peptide were conjugated to 
other proteins, their degradation increased upon serum removal (Backer and Dice 1986). 
In the case of RNase A, this pentapeptide motif consists of the amino acid sequence 
KFERQ (Dice, Chiang et al. 1986). Since the discovery of this motif, many other 
validated targets of CMA have been shown to contain a biochemically related sequence 
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(Majeski and Dice 2004; Kaushik, Bandyopadhyay et al. 2011). In general, this motif 
consists of an glutamine (Q) preceded or followed by four amino acids consisting of a 
basic (lysine, K; arginine, R), an acidic (aspartic acid, D; glutamic acid, E), a bulky 
hydrophobic (phenylalanine, F; isoleucine, I; leucine, L; valine, V) and a repeated basic 
or hydrophobic amino acid (Dice, Terlecky et al. 1990). Additionally, some CMA targets 
such as α2-microglobulin and glyceraldehyde 3-phosphate dehydrogenase can utilize the 
related asparagine (N) in place of the Q. Therefore this sequence is very relaxed, relying 
more on the charge of the amino acids in the sequence, rather than the exact sequence 
itself (Bejarano and Cuervo 2010). 
The CMA targeting motif is first recognized by the constitutive form of the heat 
shock protein Hsp70, Hsc70 (Chiang, Terlecky et al. 1989). Hsc70 is also involved in the 
folding of cytosolic proteins by recognition of exposed hydrophobic regions (Bejarano 
and Cuervo 2010). Hsc70 interacts with heat shock protein-90 (Hsp90), heat shock 
protein-40 (Hsp40), Bcl2-associated athanogene 1 protein (Bag-1), Hsp90-Hsp70 
organizing protein (Hop) and Hsp70 interacting protein (Hip) proteins to facilitate 
translocation of the substrate protein into the lysosome (Agarraberes and Dice 2001). The 
recognition of the substrate protein by Hsc70 is governed by ATP/ADP binding (Chiang, 
Terlecky et al. 1989), with the ADP-bound form having the highest affinity for protein 
substrates (Agarraberes and Dice 2001). The various co-chaperones described above may 
play a role in protein unfolding, which is crucial for substrate translocation (Chiang, 
Terlecky et al. 1989).  
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Protein substrate recognition and translocation across the lysosomal membrane is 
mediated by a protein receptor (Cuervo and Dice 1996). This receptor is a specific 
isoform of the lysosomal associated membrane protein 2, LAMP2a. There are two LAMP 
proteins found in higher eukaryotes, LAMP1 and LAMP2. These membrane proteins are 
estimated to contribute approximately 50% of all proteins in the lysosomal membrane 
(Eskelinen 2006). LAMP1 and LAMP2 are type I transmembrane proteins with a single 
transmembrane domain, a large luminal domain and a C-terminal domain. These proteins 
are heavily glycosylated, with an apparent molecular weight of 120 kDa (Carlsson, Roth 
et al. 1988; Mane, Marzella et al. 1989). LAMP2 undergoes alternative splicing to 
generate three different isoforms, LAMP2a, b, and c (Gough, Hatem et al. 1995). 
Regulation of LAMP2a expression is governed by the lysosomal compartment and not 
transcriptional upregulation of LAMP2 (Cuervo and Dice 2000). This control includes 
the regulated cleavage of LAMP2a by two lysosomal membrane proteases (Cathepsin A 
and a membrane associated metalloprotease) or the distribution of LAMP2a between the 
lysosomal membrane and matrix. The latter controls the amount of the cytosolic tail on 
the lysosomal surface (Cuervo and Dice 2000; Cuervo, Mann et al. 2003).  In CMA, 
LAMP2a interacts with protein substrates via four residues within the cytosolic tail of 
LAMP2a. These four residues mediate electrostatic interactions between substrate and 
receptor and are specific for LAMP2a as they are not found in the other LAMP2 isoforms 
(Cuervo and Dice 2000). When CMA is activated, LAMP2a is mobilized out of discrete 
membrane microdomains and away from Cathepsin A (Kaushik, Massey et al. 2006). 
Bandyopadhay et al. found that upon substrate binding, LAMP2a monomers assemble to 
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form a 700 kDa multimeric complex on the lysosomal membrane (Bandyopadhyay, 
Kaushik et al. 2008). This complex can form a channel within the lysosomal membrane 
to allow the substrate protein to translocate across the membrane. This association is very 
transient, adding to the selectivity of CMA in addition to providing a mechanism to 
prevent lysosomal leakage. After substrate translocation, LAMP2a is quickly 
disassembled through the action of cytosolic Hsc70, glial fibrillary acidic protein 
(GFAP), and elongation factor 1α (EF1α) (Bandyopadhyay, Kaushik et al. 2008; 
Bandyopadhyay, Sridhar et al. 2010). 
The translocation of the substrate protein across the lysosomal membrane is not a 
passive process. Rather, the lysosomal luminal form of Hsc70 (lys-Hsc70) engages the 
substrate to allow for its translocation across the lysosomal membrane (Agarraberes, 
Terlecky et al. 1997). Lys-hsc70 is the protein variant that confers CMA activity on a 
subset of lysosomes (Cuervo, Dice et al. 1997). Given that Hsc70 binds ATP/ADP, it is 
possible that substrate translocation is an active process, facilitated by protein unfolding 
by lys-Hsc70 (Agarraberes and Dice 2001). Conversely, Hsc70 could simply prevent the 
movement of the substrate back into the cytoplasm (Bejarano and Cuervo 2010).   
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Cross-talk between the UPS and autophagy-lysosomal pathway 
Although the UPS and autophagy-lysosomal pathways degrade different proteins 
by different mechanisms, these systems do not act independently of each other. In fact,  
numerous studies have shown that a defect in one pathway can cause the upregulation of 
another, although examples of the converse (upregulation of one pathway causes the 
downregulation of another) have not been found. Additionally, proteins involved in either 
pathway can be degraded by the other. Finally, certain proteins have been shown to be 
degraded by both pathways, independent of the stress condition of the cell. Massey et al. 
demonstrated that in cells that were selectively deficient for LAMP2a, and therefore 
defective for CMA, there was an upregulation of macroautophagy (Massey, Kaushik et 
al. 2006). Additionally, Kaushik et al. found that by inhibiting macroautophagy with 
either pharmacological inhibitors or cells deficient for Atg5, there was an upregulation of 
CMA under normal nutritional conditions as well as stress conditions (Kaushik, Massey 
et al. 2008). Additionally, pharmacological inhibition of the proteasome can lead to the 
upregulation of macroautophagy in a variety of cellular systems (reviewed in (Park and 
Cuervo 2013). Interestingly, the catalytic core of the proteasome can be degraded by 
macroautophagy under nutritional stress (Cuervo, Palmer et al. 1995). Finally, the 
selective autophagy cargo-recognition protein p62 can be degraded by both the 
proteasome and macroautophagy (Myeku and Figueiredo-Pereira 2011).  
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Figure 3. Degradation of cellular proteins by the proteasome and autophagy-
lysosomal systems. The proteasome degrades individual, often ubiquitinated, proteins 
(indicated by the light green spheres, left). Macroautophagy intiates on the isolation 
membrane as described in the text. Microautophagy involves the invagination of the 
lysosomal membrane to deliver cytosolic contents such as proteins and organelles. CMA 
depends on the recognition of a specific motif by cellular chaperones that faciliate the 
translocation of proteins across the lysosomal membrane. 
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Degradation of TRIM proteins 
Many TRIM proteins contain E3 ubiquitin ligase function, which lies within the 
RING domain at the N-terminus of the protein. This function has led to the hypothesis 
that TRIM proteins are degraded by the proteasome. However, only a handful of these 
TRIM proteins have been shown to be definitively degraded by the proteasome. 
Alternatively, there are examples that shown TRIM proteins are sensitive to inhibitors of 
lysosomal degradation. The multiple pathways of degradation utilized by TRIM proteins 
highlights the little that is known about these proteins and how the degradation of TRIM 
proteins may play a role in their cellular functions. In particular, TRIM79α, TRIM50 and 
TRIM5α have all been shown to be sensitive to both degradation pathways.  
 
TRIM79α: Flavivirus restriction factor 
TRIM79α is a murine TRIM protein identified by Taylor et al. as a interacting 
partner of the flavivirus NS5 protein (Taylor, Lubick et al. 2011). The molecular 
organization of TRIM79α is similar to TRIM5α, with the requisite RING, BBox and CC 
domains followed by a C-terminal SPRY domain. Also similar to TRIM5α, the 
expression of TRIM79α can be induced by interferon. Interestingly, TRIM79α shows 
similar tissue distribution as murine TRIM30α, a mouse TRIM5α homolog (Shi, Deng et 
al. 2008; Tareen and Emerman 2011). TRIM79α has a protein half-life of about 90 
minutes, similar to the half-life described for TRIM5α (Wu, Anderson et al. 2006). The 
interaction between TRIM79α and the flavivirus NS5 protein leads to the degradation of 
NS5, which ultimately prevents flavivirus infection (Taylor, Lubick et al. 2011).  
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Furthermore, the degradation of NS5 was species specific, in that TRIM79α prevented 
tick-borne encephalitis virus (TBEV) but not West Nile virus (WNV). The degradation of 
NS5 was not proteasomal dependent, as treatment with the lysosomal inhibitor NH4Cl 
prevented NS5 degradation, while MG132 had no effect. In the absence of restriction 
sensitive virus, TRIM79α was sensitive to proteasomal inhibition, indicating that 
TRIM79α utilizes different degradation pathways to facilitate flavivirus restriction. It is 
hypothesized that as NS5 can form large protein complexes with other viral proteins, the 
TRIM79α-mediated degradation by the lysosomal pathway in the presence of the virus 
occurs more easily then proteasomal degradation of single proteins.  
 
TRIM50: Implicated in Williams Beuren syndrome  
TRIM50 is one of 28 genes on chromosome 7 that is deleted Williams-Beuren 
patients. This microdeletion of about 1.55-1.84 Mb occurs when partially homologous 
duplicons that flank the 28-gene region misalign and subsequently lead to deletion of this 
region during meiosis (Pober 2010). This rearrangement includes the genes encoding 
TRIM73 and TRIM74. Although the molecular mechanism is poorly defined, Williams-
Beuren patients suffer from a multisystemic disease, impacting the cardiovascular, 
endocrine and nervous systems to name a few. (Micale, Fusco et al. 2008). Together, 
these data implicate TRIM proteins in multisystem development. Additionally, TRIM50 
can localize to the tubulovesicular and canalicular membranes in gastric parietal cells, 
and can direct the formation of gastric vesicles in a PI3K dependent manner (Nishi, 
Aoyama et al. 2012). Thus, there is no evidence for this TRIM protein to act a restriction 
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factor; however, the data suggests that this protein is involved in multiple cellular 
systems. 
Although the characterization of TRIM50 is limited, it has similar domain 
architecture to TRIM5α. Specifically, TRIM50 contains a RING, Bbox, CC and SPRY 
domain (Micale, Fusco et al. 2008). TRIM50 interacts with specific E2 enzymes to 
facilitate its autoubiquitination, which is dependent on the RING domain. TRIM50 
ubiquitination increases upon treatment with MG132. Interestingly, TRIM50 steady-state 
protein levels increases in the presence of NH4Cl, indicating that TRIM50 is degraded by 
autophagy-lysosomal pathway. Also of note, when autophagy is inhibited with NH4Cl, 
TRIM50 localization to ubiquitin positive cellular accumulations decreases. Finally, 
TRIM50 can interact with p62, the selective autophagy protein that can shuttle proteins to 
both the proteasome and the autophagy-lysosomal system (Pankiv, Clausen et al. 2007; 
Geetha, Seibenhener et al. 2008; Fusco, Micale et al. 2012). Thus, TRIM50 represents 
another TRIM protein whose function is altered by inhibition of either the proteasome or 
the autophagy-lysosomal pathway. 
 
TRIM5α: Association with proteins important for both degradative pathways 
As discussed previously, TRIM5α-mediated restriction of retroviral infection 
includes proteasomal dependent and independent steps (Anderson, Campbell et al. 2006; 
Chatterji, Bobardt et al. 2006; Stremlau, Perron et al. 2006; Wu, Anderson et al. 2006). 
Interestingly, only one study to date has demonstrated that the degradation of TRIM5α is 
mediated by the proteasome. Rold and Aiken demonstrated that TRIM5α protein turnover 
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was sensitive to MG132 treatment only when large amounts of restriction-sensitive virus 
is present (Rold and Aiken 2008). The authors found that infection with HIV-1 led to a 
destabilization of rhTRIM5α but not of huTRIM5α. TRIMCyp was also destabilized in 
the presence of HIV-1. Interestingly, the stability of TRIMCyp increased in the presence 
of HIV-1 and cyclosporine A (CsA). CsA can prevent CA binding by cyclophillin A. 
Therefore, when restriction by TRIMCyp is relieved, TRIMCyp regains stability. It is 
postulated that TRIMCyp degradation depends on the recognition of the viral CA protein. 
Additionally, huTRIM5α, which can potently restrict N-MLV but not B-MLV and HIV-
1, was destabilized upon N-MLV infection. Thus, various retroviruses can destabilize 
TRIM proteins that recognize species specific CA proteins, and this destabilization can 
be rescued with MG132.  
The involvement of the proteasome in restriction and the degradation of 
rhTRIM5α in the presence of specific retroviruses suggests that perhaps a molecular 
switch exists that controls the degradative fate of TRIM5α, altering its endogenous 
degradation to proteasomal degradation in the presence of virus. Recently, O’Connor et 
al. described the direct interaction of the cellular scaffolding protein p62 with rhTRIM5α 
and huTRIM5α. Furthermore, p62 localized to TRIM5α cytoplasmic assemblies and 
knock down of p62 using specific siRNA led to a decrease in TRIM5α protein levels. 
Knock down of p62 in TRIM5α expressing cells also decreased retroviral restriction, 
which can likely be attributed to the decrease in TRIM5α protein (O'Connor, Pertel et al. 
2010). p62 is a multi-domain, multifunctional protein whose expression is induced by 
interferon (Kim and Ozato 2009). p62 can shuttle proteins to the proteasome or to the 
27 
 
autophagy-lysosomal system (Pankiv, Clausen et al. 2007; Geetha, Seibenhener et al. 
2008). p62 itself appears to be degraded by both pathways (Myeku and Figueiredo-
Pereira 2011). Additionally, p62 can act as a cargo receptor for selective autophagy by 
binding ubiquitinated proteins via its UBA domain (Schreiber and Peter 2013). 
Therefore, it is possible that p62 acts as a molecular switch, altering the sensitivity of 
TRIM5α to different degradation pathways.  
p62 is one of many TRIM5α cofactors that could play a role in the degradation of 
TRIM5α. Additionally, heat shock proteins have been shown in to interact and co-
localize with TRIM5α. Specifically, Hsp70, Hsp90 and Hsc70 can interaction with 
TRIM5α (Diaz-Griffero, Li et al. 2006; Hwang, Holl et al. 2010). The association of 
Hsc70 with TRIM5α is interesting as Hsc70 is the cellular chaperone responsible for 
substrate recognition in both microautophagy and CMA (Chiang, Terlecky et al. 1989; 
Sahu, Kaushik et al. 2011). Additionally, Hsp70 and Hsp90 are co-chaperones that form a 
large complex upon substrate recognition during CMA (Majeski and Dice 2004). 
Interestingly, Hwang et al. propose that the association of Hsp70 assists in TRIM5α 
protein folding, while the role for Hsc70 in TRIM5α has not yet been identified (Hwang, 
Holl et al. 2010). 
Finally, proteins important for ubiqutination and proteasomal degradation have 
been associated with TRIM5α (Yamauchi, Wada et al. 2008; Lukic, Hausmann et al. 
2011; Pertel, Hausmann et al. 2011). TRIM5α has been shown to autoubiquitinate as well 
as ubiquitinate the related TRIM21 protein, which was dependent on the catalytic activity 
of the RING domain. Additionally, proteasomal inhibition did not stabilize TRIM5α 
28 
 
ubiquitination, demonstrating that TRIM5α is not degraded by the proteasome 
(Yamauchi, Wada et al. 2008). Both mono- and polyubiquitination of TRIM5α have been 
detected (Diaz-Griffero, Li et al. 2006; Yamauchi, Wada et al. 2008). Interestingly, 
although TRIM5α degradation is not dependent on the proteasome, Lukic et al. detected 
proteasomal subunits in TRIM5α cytoplasmic assemblies in the presence and absence of 
restriction-sensitive virus, as well as in the absence of proteasomal inhibitors (Lukic, 
Hausmann et al. 2011). Additionally, Pertel et al. demonstrated that TRIM5α can 
associate with the E2 complex, UBC13-UEV1A, that leads to the K63-linked 
ubiquitination of signaling molecules important for AP-1 and NFB activation of the 
innate immune response (Pertel, Hausmann et al. 2011). Collectively, these data 
demonstrate that both proteasomal and autophagic proteins can interact with TRIM5α, 
and these interactions cannot definitely identify the degradative fate of TRIM5α. 
 
Summary and conclusions 
 Previous studies have demonstrated that TRIM5 proteins are not degraded by the 
UPS, one of the degradation systems utilized by eukaryotic cells. We propose that 
TRIM5 proteins are degraded by the autophagy-lysosomal pathway, We hypothesize that 
TRIM5 proteins can localize to lysosomal marker proteins upon lysosomal inhibition, 
which prevents the cellular turnover of TRIM5 proteins. Furthermore, we hypothesize 
that TRIM5 proteins are degraded by CMA, which occurs solely within the lysosome. 
The route of degradation utilized by TRIM5 proteins in the absence of virus could have 
wide reaching implications. In particular, it could represent an unidentified aspect of 
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TRIM5-mediated retroviral restriction. Additionally, it could also shed light on how this 
diverse group of proteins is regulated by the host cell. 
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CHAPTER TWO 
MATERIALS AND EXPERIMENTAL METHODS 
Cell lines, viruses and pharmaceuticals 
HeLa and 293T cell lines were obtained from the American Type Culture 
Collection. TE671 cells were a gift from Dr. Thomas Hope. Cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) (HyClone, Logan UT, USA), 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 10 µg/ml ciprofloxacin. Cells were maintained in the presence of 5% CO2 at 37°C. 
To produce amphitropic MLV Env (A-MLV) pseudotyped HIV-1 GFP reporter viruses, 
293T cells were transfected with 6 ug A-MLV plasmid and 4 ug of the proviral construct 
R7Δ EnvGFP in which the Nef gene was replaced with GFP. To produce A-MLV murine 
leukemia viruses, 293T cells were transfected with equal amounts of pCigB or pCigN 
packaging plasmids, YFP reporter vector and A-MLV Env. Transfections were 
performed wih polyethylenimine (PEI). To assess virus infectivity, equivalent numbers of 
HeLa or CRFK cells were plated to assess HIV-1 or MLV reporter viruses, respectively. 
14 hours post infection, the virus was removed and normal media was added. Infectivity 
was assessed by measuring GFP or YFP fluorescence 48-72 hours later by using a 
fluorescence-activated cell sorter (FACS) Canto II (Becton Dickinson) or Accuri c6 (BD 
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Biosciences) flow cytometer. Bafilomycin A1 and MG132 (Cayman Chemical 
Company, Ann Arbor, Michigan, USA) were used at final concentrations of 100 nM and 
1 g/ml, respectively. Cycloheximide was used at a final concentration of 20 g/ml.  
Recombinant DNA constructs and generation of stable cell lines 
Cells expressing yellow fluorescent protein-tagged WT rhTRIM5α (YFP-
rhTRIM5α) and hemagglutinin (HA)-tagged WT rhTRIM5α have been described 
previously (Campbell, Dodding et al. 2007; Sastri, O'Connor et al. 2010). To generate 
mutations in the putative CMA sequences of rhTRIM5α, triple alanine mutants were 
introduced using SOEing PCR (Sastri, O'Connor et al. 2010). Subsequently, mutant 
rhTRIM5α PCR products were cloned into a pLNCX2 derived MLV retroviral plasmid 
encoding an N-terminal YFP protein tag in frame with rhTRIM5α using BamHI and 
XhoI. To generate HeLa cell lines expressing the mutant YFP-rhTRIM5α, 293T cells 
were transfected using the YFP-rhTRIM5α constructs, B-MLV packaging plasmid 
pCigB, and the envelope plasmid VSV-g. 48 hours after transfection, supernatant 
containing the retroviral particles was collected and filtered through a 0.45 m syringe 
driven filter and applied to the HeLa cells. 48 hours later, DMEM media containing G418 
replaced the original media to select for cells that were positively transduced and 
expressing YFP-rhTRIM5α. YFP-rhTRIM5α expression was confirmed by 
immunofluorescence and western blot.  
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Steady state protein analysis 
Cell lines stably expressing the indicated TRIM5α tagged protein were treated 
with BafA1 and MG132 and cells were harvested at the indicated time points. Whole-cell 
lysates were prepared by treating 2 x 10
5
 cells with lysis buffer (100 mM Tris, pH 8.0, 
1% NP-40, 150 mM NaCl) containing protease inhibitor cocktail (Roche Applied 
Science, Indianapolis, IN, USA). After lysis of cells Laemmli 2x SDS sample buffer was 
added and samples were boiled for 5 min. Equal amounts of protein, based on cell 
number at the time of harvest, were loaded into a 10% polyacrylamide gel for SDS-
PAGE. After separation of proteins via SDS-PAGE, proteins were transferred to 
nitrocellulose membranes and detected by incubation with the following antibodies: anti- 
-actin (Sigma-Aldrich, St. Louis, MO, USA), anti-HA (clone 3F10) conjugated to 
horseradish peroxidase (HRP) (Roche Applied Science, Indianapolis, IN, USA), and anti-
GFP (Clontech Laboratories, Inc, Mountain View, CA, USA). Secondary antibodies 
conjugated to HRP (Thermo Fisher Scientific, Waltham, MA, USA) were used where 
necessary, and antibody complexes were detected using SuperSignal West Femto 
chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA). 
Chemiluminescence was detected using a UVP EC3 imaging system (UVP LLCUpland, 
CA, USA).  
Protein turnover assay 
Cell lines stably expressing the indicated TRIM5α tagged protein were treated 
with cycloheximide alone or in the presence of BafA1 or MG132. Cells were harvested at 
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6 hours following cycloheximide addition. Equivalent amounts of protein from individual 
samples were subjected to SDS-PAGE and TRIM5α protein was detected by Western 
blot. 
Flow cytometry 
Equivalent numbers of cells stably expressing YFP-rhTRIM5α in a 12-well plate 
were treated with cycloheximide, BafA1, or MG132 for 6 h or 18 h, after which the cells 
were fixed in a final 10% formaldehyde-PBS solution. Protein levels were determined by 
mean fluorescence intensity (MFI) in the FITC channel for 10,000 events per sample 
using a FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA). 
Detection of endogenous huTRIM5α 
TRIM5α antibodies were acquired from the NIH AIDS reagents and resources 
program. To measure endogenous TRIM5α upon proteasomal inhibition, TE671 cells 
were used due to their high level of endogenous huTRIM5α and their ability to resist N-
MLV infection. Briefly, 1 x 10
6
 cells were evenly plated in a 6 well format. Cells were 
allowed to adhere to the plate and then DMEM supplemented with DMSO, BafA1 or 
MG132 was applied for 18 hours. Whole-cell lysates were prepared by treating cell 
pellets with lysis buffer (100 mM Tris, pH 8.0, 1% NP-40, 150 mM NaCl) containing 
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). After cell 
lysis, Laemmli 2x SDS sample buffer was added and samples were boiled for 5 min. 
Equal amounts of protein, based on cell number at the time of harvest, were loaded into a 
10% polyacrylamide gel for SDS-PAGE. Proteins were transferred to nitrocellulose and 
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membranes were probed mouse anti-TRIM5α (IF8-4) for 1 hour in 0.6% BSA in 0.03% 
PBS-T. Membranes were washed and probed with goat anti-mouse IgG conjugated-HRP 
secondary antibody overnight at 4 degrees. huTRIM5α protein amounts were detected 
with Femto chemiluminescent substrate and quantified using ImageJ.  
Immunofluorescence microscopy 
Cells were allowed to adhere to fibronectin-treated glass coverslips and fixed with 
3.7% formaldehyde (Polysciences) in 0.1 M PIPES [piperazine-N,N'-bis(2-ethanesulfonic 
acid)], pH 6.8. Cells were permeabilized with 0.1% saponin, 10% normal donkey serum, 
0.01% sodium azide in PBS. We used the following primary antibodies: rabbit anti-LC3b 
(Sigma-Aldrich, St. Louis, MO, USA) and mouse anti-LAMP2 (BD Pharmigen, San 
Diego, CA, USA). Primary antibodies were secondarily labeled with fluorophore-
conjugated donkey anti-mouse or anti-rabbit antibody (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA). Images were collected with a DeltaVision 
microscope (Applied Precision, Issaquah, WA, USA) equipped with a digital camera 
(CoolSNAP HQ; Photometrics, Tucson, AZ, USA), using a 1.4-numerical aperture (NA) 
100x objective lens, and were deconvolved with SoftWoRx software (Applied Precision, 
Issaquah, WA, USA).  
Image Analysis 
20 Z-stack images were acquired using identical acquisition parameters. Surfaces 
for cytoplasmic bodies in all samples analyzed were defined by using a fluorescence 
threshold (250 relative fluorescence units) for YFP-rhTRIM5α, and all YFP-rhTRIM5α 
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bodies over an area of 0.2 μm2 were used in the analysis. Deconvolved images were 
analyzed for LC3b and LAMP2 maximum fluorescence intensity in cytoplasmic bodies 
using the Surface Finder function of the Imaris software package ( Bitplane, Zurich, 
Switzerland) and the data were plotted in Prism (Graphpad Software Inc., La Jolla, CA, 
USA) for statistical analysis. 
siRNA transfections 
Atg5 siRNA treatment: To knockdown the expression of human Atg5 gene, we 
used two different small interfering RNAs: siRNA#1 (Cell Signaling, Danvers, MA, 
USA) consisting of 5’-GCCUGUAUGUACUGCUUUA-3' and 5’-
GCCUGUAUGUACUGCUUUA-3' and siRNA#2 (Invitrogen, Carlsbad, CA, USA). The 
siRNA were transfected using RNAMax (Life Technologies, Grand Island, NY, USA) 
according to manufacturer’s instructions.  Approximately 48 hrs following transfection 
with siRNA, the cells were treated with MG132 (10 M) or BafA1 (20 nM) overnight 
and then scraped and collected in Laemmli buffer. Lysates were separated on an 8% or 
10% polyacrylamide gel for SDS-PAGE. Proteins were transferred onto nitrocellulose 
membrane and probed with α-Atg5 (Cell Signaling, Danvers, MA, USA), α-GFP, or α--
actin antibodies.  
LAMP2 and Hsc70 siRNA treatment: Subconfluent YFP-rhTRIM5α HeLa cells 
were plated equally in a 24 well plate. Control (sc-37007) and human LAMP2 and 
Hsc70-specific siRNAs (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were 
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transfected using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) twice 
within a 24 hour period. Cells were collected at 24, 48 and 72 hours post transfection and 
subjected to Western blot analysis. Equal amounts of protein was determined by cell 
number at the time of collection. Nitrocellulose membranes were probed with α-LAMP2 , 
α-Hsc70 α-GFP, and α--actin and the appropriate secondary antibodies conjugated to 
HRP were used where necessary. Antibody complexes were detected using SuperSignal 
West Femto chemiluminescent substrate and chemiluminescence was detected using a 
ChemiDoc™ XRS+ (BioRad, Hercules, CA, USA).  
p62 siRNA treatment: Subconfluent YFP-rhTRIM5α HeLa cells were plated 
equally in a 6 well plate. Control (sc-37007) and human p62-specific siRNAs (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) were transfected using Lipofectamine 2000 
(Life Technologies, Grand Island, NY, USA) twice within a 24 hour period. Cells were 
then evenly plated on fibronectin treated coverslips. Cells were allowed to adhere before 
the addition of DMEM containing BafA1 was added for 6 hours. Cells were then fixed 
and subject to immunofluorescence analysis as described above. Endogenous p62 was 
detected using a mouse anti-p62 antibody and endogenous LC3b was detected using a 
rabbit anti-LCb antibody. Image analysis was performed as described above. 
Quantitative Real-Time PCR for viral RT products 
Detection of viral RT products with pharmacological inhibition of degradation 
pathways: Untransduced HeLa cells  or HeLa cells stably expressing HA-rhTRIM5α 
were seeded in 12-well plates at equal cell density per well and monolayers were treated 
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with BafA1 or MG132 concurrently with A-MLV Env-pseudotyped HIV-1-GFP 
infection for 18 hours at 37°C. Genomic DNA was harvested using a DNeasy tissue kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Genomic 
DNA was digested with 1 unit/l Dpn1 (New England Biolabs, Ipswich, MA, USA) for 4 
hours at 37° C to remove residual plasmid DNA. 50 ng of proviral DNA was quantified 
using primers specific for HIV-1 late RT products with SYBR green PCR reagent 
(Applied Biosystems, Carlsbad, California, USA) on a Realplex2 ep gradient 
Mastercycler (Eppendorf, Hauppauge, New York, USA). Each sample was normalized 
per 10 ng of total cellular DNA. Dilutions of proviral plasmid (10-fold) were used to 
generate standard curves for quantifying viral late RT products.   
Detection of viral RT products and infectivity with LAMP2 siRNA treatment: 
Untransduced HeLa cells or HeLa cells stably expressing hemagluttinin (HA)-rhTRIM5α 
were seeded in 6-well plates at equal cell density per well and monolayers were 
transfected with control or LAMP2 siRNA twice within 48 hours. 60 hours after the first 
transfection, cells were collected and re-plated in 24 well plates at equal cell density. 
After cells became adherent, undiluted A-MLV Env pseudotyped HIV-1 GFP, B-MLV 
YFP or N-MLV YFP were applied to the cells. BafA1 and MG132 were added where 
indicated. Cells were then spinoculated at 1200 x g for 2 hours at 13 degrees C. 
Immediately after spinoculation, viral inoculum was removed and fresh DMEM 
containing the indicated drugs was added. 12 hours post infection, cells were collected 
for viral late RT quantification. Genomic DNA was harvested and viral DNA was 
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isolated as described above. To measure viral infectivity, cells were kept in DMEM 
containing BafA1 or MG132 for 24 hours. The media was changed to normal DMEM at 
this point. At 48 hours post infection, cells were collected and fixed in 10% formaldehyde 
in PBS. Infectivity was measured by percent GFP or YFP fluorescence using a FACS 
Accuri c6 (BD Biosciences) flow cytometer. A minimum of 10,000 events were collected 
per sample.  
Statistical Analysis 
Data were statistically analyzed with GraphPad Prism 5 using one-way analysis of 
variance for comparison between no treatment, BafA1 or MG132 treated samples. 
Student’s t-test was used for the comparison of two independent groups (no treatment 
versus BafA1 treatment). For all tests, a P value of less than 0.05 was considered 
statistically significant. Chapter III 
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CHAPTER THREE 
RESULTS 
Identifying the cellular degradation pathway responsible for TRIM5α turnover 
Lysosomal inhibition alters rhTRIM5α localization 
To identify the degradative pathway responsible for the steady state degradation 
of rhTRIM5α, HeLa cells stably expressing YFP-rhTRIM5α were treated with inhibitors 
of the major degradative pathways, autophagy/lysosome or the UPS. To inhibit 
autophagy/lysosomal degradation, we used Bafilomycin A1 (BafA1), which inhibits 
lysosomal degradation by targeting the ATPase that leads to acidification of the lysosome 
(Bowman, Siebers et al. 1988). As the lysosome is the degradative compartment that 
fuses with autophagosomes, this will inhibit both macroautophagy and lysosomal 
degradation (microautophagy and CMA). To inhibit the proteasome, we used MG132, 
which prevents the entry of target proteins into the barrel proteasome (Lee and Goldberg 
1998). Although proteasomal inhibition does not lead to an accumulation in rhTRIM5α 
protein, treating rhTRIM5α expressing cells with MG132 can lead to re-distribution of 
the protein into larger cytoplasmic accumulations (Anderson, Campbell et al. 2006; Wu, 
Anderson et al. 2006). Therefore we hypothesized that there would be a re-distribution of 
rhTRIM5α protein upon lysosomal inhibition of YFP-rhTRIM5α expressing cells were 
treated with BafA1 or MG132 for 6 hours. Cells were then fixed and stained with DAPI 
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to visualize the nucleus. We found that upon treatment with BafA1, YFP-
rhTRIM5α localized to smaller, more numerous puncta compared to control or MG132 
treated cells (Figure 4 a-c). When the number of cytoplasmic bodies was quantified per 
cell using Imaris imaging software, we found that there was a statistically significant 
increase in the number of bodies per cell (Figure 4d). Additionally, we performed similar 
analysis with the lysosomal inhibitor NH4Cl. We observed the same re-localization of 
YFP-rhTRIM5α protein with NH4Cl treatment that was observed for BafA1 (data not 
shown). Given that BafA1 and NH4Cl inhibit lysosomal degradation, we hypothesize that 
the accumulations of YFP-rhTRIM5α upon BafA1 treatment are not actually cytoplasmic 
bodies but rather represent YFP-rhTRIM5α that is not yet degraded within the lysosome. 
From these data, we conclude that the lysosomal degradation pathway is important for 
controlling the steady state protein levels and localization of rhTRIM5α. 
Inhibition of the autophagy-lysosomal pathway prevents rhTRIMα degradation 
Previously, proteasomal inhibition has been shown to relieve TRIM5α mediated 
restriction of late RT products without leading to an accumulation of TRIM5α protein 
(Wu, Anderson et al. 2006). Therefore, the mechanism of TRIM5α degradation remains 
unknown. We hypothesize that autophagy is responsible for the degradation of TRIM5α. 
To test this hypothesis, we utilized YFP-rhTRIM5α HeLa cell lines to measure 
rhTRIM5α protein in the presence of UPS or autophagy-lysosome inhibitors. Cells were  
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Figure 4 Subcellular localization of YFP-rhTRIM5α changes in the presence of 
BafA1 and MG132. HeLa cells stably expressing YFP-rhTRIM5α were seeded onto 
fibronectin treated coverslips for 18 hours and treated with BafA1 or MG132. (A-C). 
Representative images of cells left untreated, treated with MG132, or treated with BafA1. 
D). To quantify the number of rhTRIM5α cytoplasmic bodies in each treatment, 20 
images were taken per treatment under identical acquisition parameters. Each image was 
analyzed using Imaris imaging software. The mean and standard error of the mean (SEM) 
are highlighted in red. ***, P<0.0001. 
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treated with BafA1 or MG132 for 18 hours. YFP-rhTRIM5α protein expression was 
assessed by western blot and flow cytometry. As shown in figure 5, compared to 
untreated cells, treatment with BafA1, but not MG132, led to an accumulation of 
rhTRIM5α, as measured by western blot. Densitometric analysis by ImageJ allowed us to 
quantify the rhTRIM5α protein levels with each treatment. As shown in figure 5b, 
rhTRIM5α protein increased ~2.5 fold with BafA1 treatment, while MG132 treatment did 
not significantly increase the protein level compared to untreated samples.  
Total rhTRIM5α protein levels were also measured by flow cytometry. Cells were 
left untreated or treated with BafA1 or MG132 for 18 hours and then fixed with 10% 
formaldehyde in PBS. The mean fluorescence intensity (MFI) of YFP-rhTRIM5α was 
determined using a FACS Canto II flow cytometer. Untransduced HeLa cells were used 
to subtract background fluorescence. Similar to the results observed with the western 
blot, BafA1 treatment resulted in a ~2.5 fold increase in MFI of YFP-rhTRIM5α, 
whereas treatment with MG132 did not lead to an increase in TRIM5α protein (figure 
5c). From these results, we conclude the lysosome is responsible for rhTRIM5α steady 
state protein degradation.  
Inhibition of the autophagy-lysosomal pathway prevents rhTRIMα protein turnover  
To determine if rhTRIM5α protein turnover occurs within the lysosome, we 
measured YFP-rhTRIM5α protein levels in the presence of cycloheximide and 
degradation inhibitors. Cycloheximide prevents new protein translation and therefore, can 
be used to measure protein degradation. Briefly, we treated YFP-rhTRIM5α HeLa cells  
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Figure 5 rhTRIM5α protein is sensitive to the autophagy inhibitor BafA1.  A) HeLa 
cells stably expressing YFP-rhTRIM5α were treated with BafA1, MG132 or left 
untreated for 18 hours. Equivalent amounts of cell lysates were analyzed via Western blot 
using antibodies for GFP and actin as a loading control. B) YFP-rhTRIM5α protein levels 
were quantified using ImageJ software. C) YFP-rhTRIM5α protein expression was 
determined by flow cytometry in YFP-rhTRIM5α positive and negative cells. Mean 
fluorescence intensity (MFI) was determined after background fluorescence was 
subtracted. Data are representative of at least three experiments. 
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with BafA1 or MG132 in the presence of cycloheximide for 6 hours. rhTRIM5α protein 
was analyzed by western blot and flow cytometry  using the same conditions as the 
steady state analysis. As shown in Figure 6a and b, we found that treatment with 
cycloheximide for 6 hours led to a significant reduction of rhTRIM5α protein levels, as 
expected based on previous estimates of rhTRIM5α half-life (Wu, Anderson et al. 2006). 
In the presence of BafA1 treatment, the levels of rhTRIM5α remained nearly constant, 
indicating that rhTRIM5α was not degraded when the lysosome was inhibited. As 
expected, treatment with MG132 did not alter rhTRIM5α protein levels. Additionally, we 
quantified total cellular protein levels using flow cytometry. As shown in Figure 6c, 
BafA1 treatment inhibited rhTRIM5α degradation, while MG132 had no effect. These 
data led us to conclude that lysosomal degradation is the main pathway responsible for 
rhTRIM5α turnover.  
Endogenous huTRIM5α degradation occurs within the lysosome 
Recently, antibodies were developed by the Hope and Sundquist labs to detect 
endogenous human and rhesus TRIM5α. These antibodies were made available through 
the NIH AIDS reagents and resources. Using the TRIM5α antibody, IF8-4, we assessed 
endogenous huTRIM5α in TE671 cells after treatment with BafA1 or MG132 for 18 
hours. As shown in figure 7, huTRIM5α was detected using this antibody, and in the 
presence of MG132, there was no significant increase in huTRIM5α protein levels 
compared to control. However, in the presence of BafA1 there was a significant increase 
in TRIM5α protein. When the relative ratio of huTRIM5α protein levels was normalized  
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Figure 6 Altered rhTRIM5α protein turnover in the presence of BafA1 or MG132. 
A) HeLa cells stably expressing YFP-rhTRIM5α were plated in triplicate, left untreated 
or treated with cycloheximide alone (CHX), CHX and BafA1 (CHX+BafA1), or CHX 
and MG132 (CHX+MG132) for 6 hours. Equivalent amounts of cell lysates were 
analyzed via Western blot using antibodies for GFP and actin as a loading control. B) 
YFP-rhTRIM5α protein levels were quantified using ImageJ software. C) YFP-
rhTRIM5α protein expression was determined by flow cytometry in YFP-rhTRIM5α 
positive and negative cells. Mean fluorescence intensity (MFI) was determined after 
background fluorescence was subtracted. Data are representative of at least three 
experiments. **, P<0.01, compared to CHX alone 
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using the endogenous -actin levels as a loading control, there was almost a ~2 fold 
increase in protein levels (Lane 2). As a control, we also probed the membranes for LC3, 
as a measure of autophagy-lysosomal inhibition. As expected, the ratio of LC3bII/LC3bI 
was almost 2:1 when BafA1 was present, which indicates that autophagy was inhibited. 
In the presence of MG132, this ratio was 1:1, which indicates that autophagy was 
activated by the extended proteasomal inhibition (Mizushima and Yoshimori 2007). This 
would agree with the decrease we observe for huTRIM5α protein levels in the presence 
of MG132 (lane 3). From these data, we conclude that endogenous huTRIM5α is  
degraded by lysosomal degradation similar to HeLa cell lines stably expressing 
rhTRIM5α. Also, these data indicate that both rhesus and human TRIM5α are sensitive to 
lysosomal degradation. 
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Figure 7 Altered endogenous huTRIM5α protein degradation in the presence of 
BafA1. TE671 cells were treated with DMSO, BafA1 or MG132 for 18 hours. Equivalent 
amounts of cell lysates were analyzed via Western blot using antibodies for TRIM5α, 
LC3 and -actin. The relative ratio of TRIM5/actin was calculated based on the 
densitometry for each sample compared to the DMSO control. The ratio of LC3II/LC3I is 
the absolute ratio based on densitometric analysis using ImageJ. Data are representative 
of at least three experiments. 
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TRIM5α is degradation via chaperone mediated autophagy  
TRIM5α localizes with the macroautophagy marker LC3 
Treatment with BafA1 inhibits all lysosomal degradation. This includes 
macroautophagy, microautophagy and chaperone mediated autophagy. To further 
characterize the lysosomal pathway that is responsible for TRIM5α degradation, we 
examined the co-localization of rhTRIM5α with the macroautophagy marker protein 
LC3b. HeLa cells stably expressing YFP-rhTRIM5α were treated with BafA1 for 6 
hours. Cells were then fixed and permeabilized with Saponin to preserve internal 
membrane structures and endogenous LC3 was detected using a rabbit anti-LC3 
antibody. Cells were also stained with DAPI to visualize the nucleus. Control and BafA1 
treated cells were imaged under identical imaging parameters and 20 images were taken 
per treatment. The co-localization between YFP-rhTRIM5α and LC3b was measured 
using Imaris imaging software. Representative images and quantification are shown in 
Figure 8. Cells were stained with secondary only to control for background staining. 
Cells that were left untreated had moderate co-localization between YFP-rhTRIM5α and 
endogenous LC3b. When cells were treated with BafA1, the localization between these 
two proteins increased significantly. As we hypothesize that upon BafA1 treatment, 
rhTRIM5α localizes to smaller more numerous puncta that are lysosomes that cannot 
degrade their contents, it is possible that the increased localization between rhTRIM5α 
and LC3b indicates autolysosomes that are inhibited from degrading their contents. 
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Figure 8 rhTRIM5α co-localizes with the autophagy marker LC3b. HeLa cells stably 
expressing YFP-rhTRIM5α were seeded onto fibronectin treated coverslips. Cells were 
left untreated or treated with BafA1 for 6 hours. Cells were fixed, permeabilized and 
immunostained with rabbit anti-LC3b and DAPI. (A and B). Representative images of 
cells left untreated (A) or treated with BafA1 (B). C). To quantify the number of 
rhTRIM5α cytoplasmic bodies that were positive for LC3b staining in each treatment, 20 
images were taken per treatment under identical acquisition parameters. Each image was 
analyzed using Imaris imaging software. ***, P<0.0001 
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p62 does not alter BafA1 sensitivity or LC3 localization of TRIM5α 
Recently, O’Connor et al. identified and characterized the TRIM5α co-factor, p62 
(O'Connor, Pertel et al. 2010). p62 is a multifunctional protein that has been implicated in 
protein trafficking to degradative pathways, including proteasomal and autophagsomal 
degradation (Pankiv, Clausen et al. 2007; Geetha, Seibenhener et al. 2008). Additionally, 
it was shown that p62 was important for rhTRIM5α protein stability; when p62 was 
knocked down using siRNA, TRIM5α protein levels decreased. Therefore, we 
hypothesized that p62 was important for rhTRIMα degradation. Specifically, we 
hypothesized that knockdown of p62 would decrease LC3b localization with rhTRIM5α. 
To test this hypothesis, HeLa cells stably expressing YFP-rhTRIM5α were treated with 
p62-specific siRNA for two days and then co-localization with LC3b was assessed in the 
same manner as described above. As shown in figure 9, p62 knockdown decreased 
overall TRIM5α protein expression, as expected. However, the degree to which LC3b 
localized to TRIM5α was not decreased compared to control treated cells. Additionally, 
when control or p62 siRNA treated cells were treated with BafA1, the increase of YFP-
rhTRIM5α puncta, as well as the degree of co-localization with LC3b, remained the 
same. Therefore, we conclude that p62 is not important for the localization of rhTRIM5α 
to LC3b. Additionally, as p62 siRNA cells are still sensitive to BafA1, we hypothesize 
that p62 is not important for TRIM5α lysosomal degradation.  
rhTRIM5α localizes with the lysosomal membrane protein LAMP2  
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Figure 9 rhTRIM5α co-localizes with the autophagy marker LC3b independent of p62. 
HeLa cells stably expressing YFP-rhTRIM5α were transfected with p62 specific siRNA. Cells 
were then seeded onto fibronectin treated coverslips. Cells were fixed, permeabilized and 
immunostained with rabbit anti-LC3b, mouse anti-p62 and DAPI. (A and B). Representative 
images of cells left untreated (A) or treated with BafA1 (B). C). To quantify the number of 
rhTRIM5α cytoplasmic  bodies that were positive for LC3b staining in each treatment, 20 images 
were taken per treatment under identical acquisition parameters. Each image was analyzed using 
Imaris imaging software. ***, P<0.0001 
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It has been postulated that BafA1 can prevent the fusion of autophagosomes with 
lysosomes under certain conditions (Klionsky, Elazar et al. 2008). Therefore, in order to 
determine if the localization of YFP-rhTRIM5α after treatment with BafA1 was to lysosomes or 
autophagosomes that didn’t fuse with lysosomes, we assessed the co-localization of YFP-
rhTRIM5α with LAMP2. LAMP2 is a lysosomal marker protein. Therefore, if YFP-rhTRIM5α 
was actually trapped in autophagosomes upon BafA1 treatment, we would expect that, 
with BafA1 treatment, there would be no change in localization with LAMP2. However, 
if YFP-rhTRIM5α was trapped in lysosomes or autolysosmes upon BafA1 treatment, we 
would expect that co-localization with LAMP2 would increase with BafA1 treatment. To 
measure co-localization with LAMP2, cells were seeded on glass coverslips and treated 
with BafA1 for 6 hours. To detect endogenous LAMP2, cells fixed, permeabilized with 
Saponin and stained with a mouse anti-LAMP2 antibody. As shown in figure 10, YFP-
rhTRIM5α co-localized with LAMP2 in the absence of drug; however, in the presence of 
BafA1, there was increased localization between YFP-rhTRIM5α and LAMP2. Given 
that YFP-rhTRIM5α can also localize with LC3b, we hypothesize that YFP-rhTRIM5α is 
localized with lysosome or autolysosomes upon treatment with BafA1, and not 
autophagosomes that did not fuse with lysosomes.  
rhTRIM5α degradation is not changed with Atg5 knockdown 
The localization of rhTRIM5α with markers of both autophagosomal and 
lysosomal degradation led us to examine if rhTRIM5α is degraded by macroautophagy. 
As BafA1 will not differentiate between these two pathways, we used siRNA to inhibit  
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Figure 10 rhTRIM5α co-localizes with the autophagy marker LAMP2. HeLa cells 
stably expressing YFP-rhTRIM5α were seeded onto fibronectin treated coverslips. Cells 
were left untreated or treated with BafA1 for 6 hours. Cells were fixed, permeabilized 
and immunostained with mouse anti-LAMP2 and DAPI. (A and B). Representative 
images of cells left untreated (A) or treated with BafA1 (B). C). To quantify the number 
of rhTRIM5α cytoplasmic bodies that were positive for LC3b staining in each treatment, 
20 images were taken per treatment under identical acquisition parameters. Each image was 
analyzed using Imaris imaging software. ***, P<0.0001 
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macroautophagy (Kaushik, Massey et al. 2008). Specifically, we treated cells with Atg5 
siRNA to prevent for the formation of the isolation membrane in the initial stages of 
macroautophagy  (Weidberg, Shvets et al. 2011). HeLa cells stably expressing YFP- 
rhTRIM5α were treated with control or Atg5 siRNA and then collected and lysed for 
western blot analysis. As shown in figure 11, knockdown of Atg5 did not result in the 
increase of TRIM5α protein compared to control siRNA treated cells (lanes 1 and 2). To 
determine if YFP-rhTRIM5α was degraded by the lysosome when macroautophagy was 
inhibited, siRNA treated cells were treated with BafA1 or MG132. Lanes 3 and 4 of 
figure 11 show that upon Atg5 knockdown, rhTRIM5α was still sensitive to BafA1. 
rhTRIM5α protein remained insensitive to MG132 when macroautophagy was inhibited. 
These results indicate lysosomal degradation, and not macroautophagy, is responsible for 
the degradation of rhTRIM5α.  
Knock down of the CMA proteins LAMP2 and Hsc70 decreases rhTRIM5α 
degradation 
The significance of protein degradation that occurs solely within the 
lysosome is increasing. Pathways that are classified as lysosomal degradation 
include chaperone mediated autophagy (CMA) and microautophagy. Previously, 
it was shown that rhTRIM5α can interact with Hsc70, a protein important for 
CMA (Hwang, Holl et al. 2010). These data, along with the data that show that 
rhTRIM5α is degraded within lysosomes and not autophagosomes, led us to 
hypothesize that rhTRIM5α is degraded by CMA. To test this hypothesis, we  
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Figure 11 rhTRIM5α protein is sensitive to BafA1 in the presence of Atg5 
knockdown.HeLa cells stably expressing YFP-rhTRIM5α were treated with control or 
Atg5 siRNA. Cells were  then treated with BafA1 or MG132 for 18 hours. Protein 
expression was measured by Western blot. Equivalent amounts of cell lysates were 
probed with antibodies to Atg5, YFP and actin. B) YFP-rhTRIM5α protein levels were 
quantified using ImageJ software. YFP-rhTRIM5α protein levels were determined as a 
percentage of control siRNA treated cells. 
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utilized LAMP2 siRNA to inhibit CMA. During CMA, LAMP2a protein multimerizes to 
form a channel from the cytosol to the interior of the lysosome; this allows for the 
substrate protein to enter the lysosome from the cytosol (Bandyopadhyay, Kaushik et al. 
2008). Therefore, using LAMP2 siRNA will prevent the formation of the channel 
required for CMA and thus prevent rhTRIM5α degradation if CMA is the pathway 
responsible. Cells were treated with control or LAMP2 siRNA following a two day 
protocol and then cellular protein levels were assessed by western blot analysis. As 
shown in figure 12, knockdown of LAMP2 led to a ~2.5 fold increase in TRIM5α protein 
levels. Additionally, we used siRNA to the chaperone Hsc70, which recognizes and 
guides the CMA substrate protein to the lysosome to be degraded (Chiang, Terlecky et al. 
1989). Therefore, we would expect that if rhTRIM5α was degraded by CMA, then 
knocking down Hsc70 would prevent the localization of rhTRIM5α to the lysosome and 
lead to an accumulation of YFP-rhTRIM5 α. As shown in figure 13, similar to LAMP2 
knockdown, Hsc70 siRNA led to an accumulation of YFP-rhTRIM5α. Therefore, we 
conclude that rhTRIM5α is degraded by the lysosomal pathway CMA.  
rhTRIM5α degradation by CMA is dependent on a motif in the coiled-coil domain 
CMA depends on the recognition of a pentapeptide motif by Hsc70 and 
other components of the chaperone complex to guide the substrate to the 
lysosome (Terlecky, Chiang et al. 1992). This pentapeptide motif is hypothesized 
to be in ~30% of cytosolic proteins, meaning the possible substrates for CMA are 
great in number (Chiang and Dice 1988). Additionally, the pentapeptide motif is  
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Figure 12 Reduced LAMP2 leads to increased rhTRIM5α protein. A) HeLa cells 
stably expressing YFP-rhTRIM5α were treated with control or LAMP2 siRNA for 48 
hours. Protein expression was measured by Western blot. Equivalent amount of cell 
lysates were probed with antibodies to LAMP2, YFP and actin. B) YFP-rhTRIM5α 
protein levels were quantified using ImageJ software. YFP-rhTRIM5α protein levels 
were determined as a percentage of control siRNA treated cells. Black bars indicate the 
amount of LAMP2 while gray bars indicate the amount of YFP-rhTRIM5α. The numbers 
on each bar represent the fold change in protein levels compared to control siRNA treated 
cells.
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Figure 13 Reduced Hsc70 and LAMP2 leads to increased rhTRIM5α protein. 
A) HeLa cells stably expressing YFP-rhTRIM5α were treated with control, 
LAMP2 or Hsc70 siRNA for 48 hours. Protein expression was measured by 
Western blot. Equivalent amount of cell lysates were probed with antibodies to 
LAMP2, Hsc70, YFP and actin. B) YFP-rhTRIM5α protein levels were quantified 
using ImageJ software. YFP-rhTRIM5α protein levels were determined as a 
percentage of control siRNA treated cells. Blue bars indicate the amount of 
LAMP2; The amount of Hsc70 is shown in red; YFP-rhTRIM5α is in green and 
actin is in purple. The numbers on each bar represent the fold change in protein 
levels compared to control siRNA treated cells. 
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characterized not by specific residues per se but rather by the location of certain 
charged residues within a motif. Therefore, we examined the coding sequence of 
rhTRIM5α for possible CMA motifs. We identified three possible motifs as 
shown in figure 14a. To examine these motifs in TRIM5α, we used SOEing PCR 
to introduce triple alanine residues within the middle of the motif and cloned 
these mutant TRIM5α cDNAs into retroviral vectors to generate YFP-expressing 
fusion TRIM5α proteins. To test if these mutations prevented CMA degradation, 
we assessed the protein sensitivity to BafA1 induced accumulation. Therefore, 
HeLa cells stably expressing the YFP-rhTRIM5α CMA mutants were treated with 
BafA1 for 6 hours. Cells were fixed and stained with DAPI to visualize the 
nucleus. Images were acquired under identical imaging parameters. Mutating the 
putative CMA sequences at residues 77-79 (L1 domain) and 258-260 (L2 domain) 
to contain triple alanine residues did not change the sensitivity of TRIM5α to 
BafA1 (Figure 14 c and e). Therefore, we conclude that these residues are not 
responsible for the degradation by CMA of TRIM5α. However, the residues from 
190-192 (CC domain) did not demonstrate the BafA1 sensitivity that wild-type 
and the other mutant showed. In fact, there was no difference in this mutant 
rhTRIM5α localization when BafA1 was used to inhibit lysosomal degradation 
compared to the control, untreated cells (Figure 14 d). Therefore, we conclude 
that rhTRIM5α is degraded by CMA and that the CC domain contains the specific 
pentapeptide motif necessary for CMA recognition and degradation.  
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Figure 14 Identification and characterization of putative CMA sequences in rhTRIM5α. A) 
The coding sequence of rhTRIM5α is shown, with known domains indicated. The underlined 
sequences highlight the putative CMA sequences based on their biochemical composition. * 
indicate sequences that are biochemically related to known CMA substrates (Adolase B and 
aspartate aminotransferase, respectively) B-E)  HeLa cells stably expressing YFP-rhTRIM5α WT 
(B), L1 CMA mutant (C), CC CMA mutant (D) and L2 CMA mutant (e), treated with DMSO 
(left panels) or BafA (right panels) for 6 hours.  
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rhTRIM5α protein degradation is important for retroviral restriction 
BafA1 does not change retroviral restriction of late viral RT products 
Given that CMA is responsible for the degradation of rhTRIM5α, we sought to 
determine if the degradation of rhTRIM5α is important for retroviral restriction. Namely, 
we sought to determine if the inhibition of rhTRIM5α degradation could change the 
restriction profile of this protein. rhTRIM5α can potently inhibit the accumulation of late 
reverse transcriptase products, which is an early step in viral replication that occurs after 
or concurrent with viral uncoating (Stremlau, Owens et al. 2004). Additionally, 
rhTRIM5α can inhibit the formation of 2LTR circles which act as a marker for viral 
genome entry into the nucleus (Wu, Anderson et al. 2006). The inhibition of these steps 
prevents the virus from integrating into the host genome and infection is inhibited. 
Additionally, while the proteasome has no effect on the degradation of rhTRIM5α, it is 
known that treatment of TRIM5α expressing cells with proteasome inhibitors can relieve 
the restriction of late RT products, but retroviral infectivity remains restricted (Wu, 
Anderson et al. 2006). We hypothesize that inhibition of rhTRIM5α lysosomal 
degradation is important for the mechanism of retroviral restriction. To measure 
rhTRIM5α restriction of HIV-1 when lysosomal degradation is inhibited, cells were 
treated with BafA1 for 18 hours with concurrent amphitropic MLV envelope 
pseudotyped R7 GFP reporter virus. This envelope mediates the entry of viruses 
independent of viral endocytosis and therefore, infection will not decrease when cells are 
treated with BafA1. Cells were lysed and genomic and viral DNA was extracted. Viral 
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late RT products were quantified using real time PCR using viral specific primers. As 
shown in figure 15, treatment with BafA1 has no effect on the restriction of late RT 
products by rhTRIM5 α. As expected, treatment of cells with MG132 rescued the 
production of viral late RT products, as described previously (Wu).  
 
LAMP2 knock down increases retroviral restriction of B-MLV by rhTRIM5α 
Although BafA1 did not change the restriction profile of rhTRIM5α, we hypothesized 
that the degradation of rhTRIM5α is important for retroviral restriction. Given that we 
hypothesize that rhTRIM5α is degraded by CMA, it is possible that BafA1 inhibits 
rhTRIM5α that is already sequestered in lysosomes. Therefore we sought to measure 
viral late RT products and infectivity when CMA specifically was inhibited with LAMP2 
siRNA. If LAMP2a is responsible for the translocation of rhTRIM5α into the lysosomes, 
then when LAMP2 was knocked down, there should be an accumulation of rhTRIM5α in 
the cytoplasm, thus increasing the population of rhTRIM5α available to restrict retroviral 
infection. HeLa cells stably expressing HA-rhTRIM5α were knocked down for LAMP2 
following a two day siRNA protocol. Cells were then infected with A-MLV R7 Env 
GFP for 12 hours concurrent with BafA1 treatment. At this point in the viral life cycle, 
viral late RT products are at a maximum and therefore easily detectable. Additionally, 
cells were infected with A-MLV pseudotyped B and N-MLV in the presence of BafA1 
and MG132. The drug containing media was replaced with normal DMEM at 24 hours 
post infection, and cells were collected at 48 hours post infection to assess viral 
infectivity by GFP or YFP fluorescence. Figure 16a demonstrates that LAMP2 knock 
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Figure 15 rhTRIM5α mediated restriction of viral late RT products is not affected 
by lysosomal inhibition. Untransduced HeLa cells (A) or HeLa cells stably expressing 
HA-rhTRIM5α (B) were plated in equivalent numbers and infected with amphitropic 
MLV Env pseudoptyped HIV-1 reporter virus for 18 hours with BafA1 or MG132. Cells 
were harvested and viral DNA products were analyzed by quantitative PCR. Values were 
normalized to 10 ng of total DNA in identical samples. Error bars represent the SEM 
from triplicate samples. Values above the columns represent fold enchancement relative 
to the level for the untreated sample of that cell type. 
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down at 48 hours post infection was robust, with a near complete depletion of LAMP2 in 
both untransduced HeLa and HA-rhTRIM5α expressing cells compared to control siRNA 
treated cells. The results of the late RT analysis are shown in Figure 16b. Inhibiting 
lysosomal degradation either with BafA1 alone or LAMP2 siRNA treatment slightly 
diminished the production of late RT products in HeLa cells. This could be due in part to 
cellular toxicity of the combination of siRNA and drug treatment. In HA-rhTRIM5α 
expressing cells, the late RT products remain restricted, indicating that inhibiting 
TRIM5α degradation does not relieve restriction. This is in contrast to treatment with the 
proteasomal inhibitor MG132, which can relieve the restriction of viral late RT products 
to the levels of HeLa cells. Interesting, in HA-rhTRIM5α expressing cells that were both 
knocked down for LAMP2 and treated with BafA1 there was a statistically significant 
decrease compared to DMSO treated cells. Although BafA1 led to slight a diminution of 
late RT products in the presence of BafA1 alone, these results suggests that there is a 
rhTRIM5α dependent decrease in viral late RT products when all lysosomal degradation 
is inhibited.  
We also measured the effect of LAMP2 knock down on viral infectivity, 
specifically HIV-1, B-MLV and N-MLV. N-MLV was completely restricted in HeLa 
cells as expected, even though infectious virus was produced as evidenced by the titration 
of this virus on CRFK cells (Figure 15d). Similar to the results obtained for the late RT 
assay, BafA1 caused a slight decrease in viral infectivity, independent of TRIM5α 
expression (Figure 15c). As we used virus pseudotyped with A-MLV envelope, the 
decrease may be due to cellular toxicity, as BafA1 should not have affected viral entry.
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We found that rhTRIM5α cells remained restricted for HIV-1 infection (left panel). 
However, we detected a rhTRIM5α-dependent decrease in B-MLV infectivity when 
LAMP2 was knocked down (right panel). This decrease was potentiated in the presence 
of BafA1. The complete inhibition of B-MLV infection in the presence may due to 
cellular toxicity from the extended MG132 treatment, as there was increased cell death 
prior to analysis. These data suggest that rhTRIM5α can restrict B-MLV infection when 
lysosomal degradation is inhibited, indicating a role for the lysosomal degradation in the 
restriction profile of rhTRIM5α.   
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Figure 16 rhTRIM5α mediated restriction of B-MLV is enhanced by LAMP2 siRNA. A) 
Untransduced HeLa cells or HeLa cells stably expressing HA-rhTRIM5α were treated with 
control or LAMP2 specific siRNA for 2 days. Cell lysates were analyzed for LAMP2 protein 
levels 48 hours later. B) siRNA treated cells were plated in equivalent numbers and infected with 
amphitropic MLV Env pseudoptyped HIV-1 reporter virus for 12 hours with BafA1. Cells were 
harvested and viral DNA products were analyzed by quantitative PCR. Quantity of viral late RT 
products is expressed as a ratio to actin. Error bars represent the SEM from triplicate samples. * 
indicates a p>0.05 from a student’s T test. C) siRNA treated cells were plated in equivalent 
numbers and infected with A-MLV Env pseudotyped HIV-1 and B-MLV reporter viruses for 24 
hours in the presence of BafA1 or MG132. Cells were collected 48 hours post infection and 
infectivity was assess by flow cytometry. D) Titration of A-MLV Env pseudotyped B- and N-
MLV on CRFK cells.  
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CHAPTER FOUR  
DISCUSSION 
Degradation of rhTRIM5α and huTRIM5α by the autophagy-lysosomal pathway 
Many studies have found that retroviral restriction by TRIM5α includes a step 
that is sensitive to proteasomal inhibition. It is well established that this step allows the 
production of viral late RT products but 2LTR circles and infectivity remains inhibited 
(Wu, Anderson et al. 2006). Additionally, proteasomal inhibition reveals that during 
rhTRIM5α-mediated restriction, a functional preintegration complex forms and these 
complexes are competent for nuclear import (Anderson, Campbell et al. 2006). Also, 
proteasomal inhibition results in the accumulation of HIV-1 virions in TRIM5α 
containing cytoplasmic assemblies (Campbell, Perez et al. 2008). In spite of these data, 
proteasomal inhibition does not inhibit TRIM5α degradation, unless restriction sensitive 
virus is present (Rold and Aiken 2008). Therefore, the degradative pathway responsible 
for TRIM5α turnover and the role for this degradation in TRIM5α-mediated restriction 
was unclear.  
In order to understand which cellular pathway is responsible for TRIM5α 
degradation, we used pharmacological inhibitors of the two main degradative pathways, 
the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway. Upon 
treatment of YFP-rhTRIM5a expressing HeLa cells with BafA1, an inhibitor of 
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lysosomal degradation, or MG132, which inhibits the UPS, we found that both treatments 
led to the re-distribution of YFP-rhTRIM5α. Inhibition of the UPS by MG132 caused 
YFP-rhTRIM5α to localize to fewer, larger cytoplasmic accumulations, as previously 
described (Wu, Anderson et al. 2006; Campbell, Perez et al. 2008). Inhibition of the 
autophagy lysosomal pathway by BafA1 led to the formation of smaller, more numerous 
YFP-rhTRIM5α accumulations (Figure 3). As BafA1 prevents degradation within the 
lysosome, it is possible that the localization of YFP-rhTRIM5α to these smaller 
accumulations represents YFP-rhTRIM5α trapped within lysosomes that cannot be 
degraded within this department. In support of this fact, we found that BafA1 increases 
the localization of YFP-rhTRIM5α to LC3 and LAMP2, proteins that serve as markers 
for the autophagosome and the lysosome, respectively (Figures 7 and 9). Additionally, 
we found that BafA1 treatment inhibits both the steady-state degradation and cellular 
turnover of rhTRIM5α (Figures 4 and 5). Collectively, these data indicate that YFP-
rhTRIM5α is degraded by the autophagy-lysosomal pathway. 
Since the discovery of rhTRIM5α as the cellular protein responsible for the 
species specific inhibition of HIV-1 and other retroviral infections, most studies of 
TRIM5 proteins have relied on cell lines expressing epitope tagged versions of this 
protein. This is due in part to the lack of reliable antibodies for the detection of 
endogenous TRIM5 proteins. The difficulty in generating specific antibodies can be 
attributed to the structural similarities between TRIM proteins (see Figure 2). However, 
recent collaboration between the Sundquist and Hope labs have generated monoclonal 
antibodies that can reliably and specifically detect endogenous human and rhesus 
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TRIM5α. Therefore, we used these antibodies to determine if endogenous human 
TRIM5α is also sensitive to inhibition of lysosomal degradation by BafA1.We found that 
in TE671, a human cell line that can inhibit N-MLV infection via huTRIM5α (Perron, 
Stremlau et al. 2004), there was a specific increase in huTRIM5α protein levels (Figure 
6). Interestingly, treatment with MG132 resulted in a slight diminution of huTRIM5α 
protein in this assay. This decrease could possibly indicate that extended proteasomal 
inhibition in TE671 cells can increase lysosomal flux more rapidly than HeLa cells, as we 
saw no decrease in protein with MG132 in HeLa cells. These data were supported by the 
relatively similar levels of LC3 I and LC3II, which indicates increased degradation 
through the autophagy-lysosomal pathway (Mizushima and Yoshimori 2007).  
Previously, it was reported that TRIM5 proteins are only sensitive to proteasomal 
degradation when restriction sensitive virus is present (Rold and Aiken 2008). This 
change in degradation was found to be conserved amongst rhesus, human and owl 
monkey TRIM5 proteins. Interestingly, TRIM5α proteins only become sensitive to 
proteasomal inhibition when destabilized by the retroviral CA protein. It is possible that 
with the stress of infection, TRIM5α proteins are degraded by the cell in order to ensure 
cellular survival, as has been the case for other proteins. Therefore, the proteasomal 
degradation of TRIM5α solely in the presence of restriction sensitive virus does not 
indicate the natural route of TRIM5α protein degradation. 
TRIM proteins can act as E3 ubiquitin-ligases, an activity conferred by the N-
terminal RING domain (Napolitano and Meroni 2012). Additionally, TRIM5α was found 
to ubiquitinate itself as well as other cellular proteins (Diaz-Griffero, Li et al. 2006; 
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Yamauchi, Wada et al. 2008; Pertel, Hausmann et al. 2011). Specifically, TRIM5α led to 
the K63-linked polyubiquitination of TAK1, a cellular protein necessary for AP-1 and 
NFkB innate immune signaling. Traditionally, K48-linked ubiquitin is thought to signal 
proteasomal degradation, while K63-linked ubiquitination can signal other fates for the 
substrate protein, such as protein localization or signaling. A recent publication revealed 
that both K48 and K63 linked ubiquitination can facilitate lysosomal degradation (Zhang, 
Xu et al. 2013), expanding the cellular role for ubiqutination. The present study does not 
address the role for TRIM5α ubiquitination and lysosomal degradation, although the 
hypothesis that ubiquitination of TRIM5α leads to lysosomal degradation deserves 
further study. Ultimately, the present study suggests that the ubiquitination of TRIM5α 
does not signal its degradation by the proteasome.  
 
Degradation of rhTRIM5α by chaperone mediated autophagy 
Our data demonstrate that the inhibition of lysosomal degradation with BafA1 
prevents the degradation of TRIM5α. However, there are multiple cellular pathways that 
lead to lysosomal degradation. Interestingly, TRIM5α has been shown to directly act with 
cellular proteins involved in two of these pathways, Hsc70 and p62 (Hwang, Holl et al. 
2010; O'Connor, Pertel et al. 2010). Hsc70 is chaperone that guides substrate proteins to 
the lysosome in chaperone mediated autophagy (CMA) while p62 is a cargo receptor 
protein involved in selective macroautophagy  (Terlecky, Chiang et al. 1992; Schreiber 
and Peter 2013). We found that upon p62 knock down with specific siRNA, there was no 
change in BafA1 sensitivity of rhTRIM5α. Additionally, there was no change in the 
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degree of localization of LC3 to YFP-rhTRIM5α assemblies (Figure 8). These data 
indicate that p62 is not responsible for the selective macroautophagic degradation of 
rhTRIM5α. We also found that upon inhibition of macroautophagy with Atg5 specific 
siRNA, rhTRIM5α protein degradation remained inhibited with BafA1 treatment (Figure 
10). Collectively, these data indicate that macroautophagy is not the pathway that 
degrades rhTRIM5α in the lysosome. However, we found that when we specifically 
inhibited CMA dependent lysosomal degradation by knocking down LAMP2, the protein 
receptor for CMA, and Hsc70, there was an accumulation of rhTRIM5α protein, in the 
absence of BafA1 treatment (Figures 11 and 12).   
All validated substrates of CMA contain a pentapeptide motif that is recognized 
by Hsc70 to facilitate their degradation within the lysosome (Majeski and Dice 2004). 
However, this sequence is relies on the organization of certain charge residues, and not 
on the specific amino acids to direct substrates to the lysosome. The sequence consists of 
a glutamine (Q) preceded or followed by four amino acids consisting of a basic (lysine, 
K; arginine, R), an acidic (aspartic acid, D; glutamic acid, E), a bulky hydrophobic 
(phenylalanine, F; isoleucine, I; leucine, L; valine, V) and a repeated basic or 
hydrophobic amino acid (Dice, Terlecky et al. 1990). Additionally, some CMA targets 
can utilize the related asparagines (N) in place of the Q.  Additionally, the CMA motif 
can be found at any position within the protein. However, the protein must be exposed for 
Hsc70 to bind the protein through unfolding or loss of interacting proteins that mask the 
motif  (Kaushik and Cuervo 2012). In this way, single proteins of a multimer may be 
degraded by CMA. Finally, post translational modification can impart the necessary 
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charge to a given amino acid in a manner that now makes the protein targeted for CMA 
(Thompson, Aiken et al. 2009; Lv, Li et al. 2011). Using these criteria we identified three 
putative sequences within rhTRIM5α. Two of these motifs (QLREI, 189-192 and 
KRIEN, residues 257-261) are biochemically similar to the validated CMA targets 
aldolase B and aspartate aminotransferase, respectively (Majeski and Dice 2004). The 
putative sequence at residues 76-80 does not share biochemical similarities to known 
sequences; however it does meet the requirement as a CMA target sequence. 
Additionally, all three motifs are well conserved between rhesus, human and gorilla 
TRIM5α, with the most diversity found in the residues that span 257-261 (data not 
shown). We mutated the core three residues of each of these motifs to alanines and 
expressed the mutant TRIM5α protein as a YFP fusion protein. When stably expressed in 
HeLa cells, the mutations of residues 77-79 and 258-260 remained sensitive to BafA1 
(Figure 13). However, the mutation of residues 190-192 was not sensitive to BafA1. 
Interestingly, the two mutants that demonstrated BafA1 sensitivity formed cytoplasmic 
assemblies that resemble wild-type rhTRIM5α, while the mutation at 190-192 was 
diffuse and remained diffuse with BafA1 treatment. The coiled-coil domain, which is 
where these residues lie, is important for TRIM protein dimerization (Reddy, Etkin et al. 
1992). Additionally, the coiled coil of rhTRIM5α has been shown to be under positive 
selective pressure to recognize the retroviral capsid (Johnson and Sawyer 2009). 
Specifically, residues 186, 214 and 229 of the coiled coil domain can modulate retrovirus 
specificity (Maillard, Ecco et al. 2010). However, no study has identified residues 189-
192 to be important to retroviral restriction. Future studies to investigate the role of the 
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putative CMA motif in the coiled-coil domain of rhTRIM5α in retroviral restriction will 
allow us to further understand the mechanism of restriction.  
 
rhTRIM5α degradation alters the retroviral restriction profile 
  As proteasomal involvement in TRIM5α mediated restriction has been well 
documented, we sought to understand if the lysosomal degradation of rhTRIM5α 
contributed to retroviral restriction. We assessed the possible role of lysosomal 
degradation two ways. First, we treated HA-rhTRIM5α expressing HeLa cells 
concurrently with BafA1 during A-MLV Env psuedotyped HIV-1 reporter virus. We then 
analyzed the viral late RT products for changes in restriction in the presence of BafA1. 
As shown in figure 14, BafA1 did not change the restriction profile in this analysis, while 
MG132 relieved the restriction of late RT products to the levels of the HeLa control. To 
assess the role for lysosomal degradation in another, we measured viral late RT products 
and infectivity in the presence of LAMP2 knock down. We hypothesize that BafA1 
treatment sequesters rhTRIM5α to lysosomes, thereby preventing TRIM5α availability to 
restrict the incoming virus particle. Therefore, we inhibited TRIM5α localization to the 
lysosome using LAMP2, as the transcript variant LAMP2a is important for CMA-
dependent localization to the lysosome. Under these conditions, we found a small, but 
statistically significant difference in the amount of viral late RT products between 
LAMP2 siRNA treated cells with or without BafA1 in rhTRIM5α expressing cells. We 
hypothesize that as LAMP2 siRNA can increase the amount of rhTRIM5α protein, this 
slight diminution in viral RT products represent the ability of TRIM5α to recognize the 
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viral capsid more efficiently because the protein is stabilized. The particular cell line used 
in this experiment expresses a large amount of rhTRIM5α. Therefore, we would expect in 
a cell line that expressed a more biologically relevant amount of TRIM5α, this difference 
would increase.  
When we measured B-MLV infectivity in the presence of LAMP2 knock down, 
we saw a similar trend to the viral late RT assay. That is, LAMP2 knock down in 
rhTRIM5α expressing cells prevented B-MLV restriction more efficiently the control 
siRNA treated cells. B-MLV infection is normally uninhibited by TRIM5α expression. 
However, similar to the results of the late RT data, it is possible that increased rhTRIM5α 
available to recognize the retroviral capsid allows for more restriction to occur.  
Therefore, we conclude that the degradation of rhTRIM5α through the lysosome via 
CMA is important for restriction of HIV-1 and B-MLV. It is possible that the mechanism 
of restriction in this case arises from the increased amount of restriction factor present 
upon LAMP2 knock down.  
 
Conclusion 
 This study presents evidence that the retroviral restriction factor rhTRIM5α is 
degraded via the lysosomal pathway chaperone mediated autophagy. We have 
demonstrated that inhibition of chaperone mediated autophagy prevents the degradation 
of rhTRIM5α, possibly through the recognition of a pentapeptide motif in the coiled-coil 
region of rhTRIM5α. Additionally, we found that when CMA is inhibited specifically 
using siRNA, there is an increase in rhTRIM5α mediated restriction of B-MLV, which is 
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normally unrestricted by TRIM5α. Therefore, the cellular degradation of rhTRIM5α may 
participate in the mechanism of retroviral restriction.
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Figure 17 Model of CMA-mediated degradation of TRIM5α A. TRIM5α protein 
degradation in the absence of restriction sensitive virus. The basal degradation of 
TRIM5α is insensitive to proteasomal inhibition. Treatment of TRIM5α expressing cells 
with lysosomal inhibitors such as BafA1 prevents CMA and leads to phenotypic changes 
in TRIM5α protein localization and turnover. B. TRIM5α protein degradation in the 
presence of restriction sensitive virus. During retroviral infection, TRIM5α binds 
determinants in the retroviral capsid that lead to the destabilization of TRIM5α and the 
capsid protein itself. Under these conditions, TRIM5α protein localization and turnover is 
sensitive to proteasomal inhibitors, indicating a change in the degradation pathway 
utilized by the host cell.  
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